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Stroke, a life-threatening medical condition, is the fifth-leading cause of death in 
the United States with an estimated annual cost of treatments above $70 billion. A 
combination of innovative approaches was used in our lab to optimize the pre-clinical 
stroke research design by choosing the most appropriate animal model and methodologies 
to increase the translational capability of the stroke research.  
The first study, modeled after ongoing clinical trials using fluoxetine, refined the 
appropriate timing of fluoxetine and ascorbic acid delivery if a rat was on simvastatin for 
7 days pre-stroke and throughout the remainder of the study.   Administration of fluoxetine 
and ascorbic acid at  6-12 hours or 48-54 hours (the time used in clinical trials) after stroke  
in male 10-12 month old rats resulted in larger infarct volume and indicated a high risk of 
hemorrhagic transformation, while administration of the same drugs 20-26 hours after 
stroke dramatically reduced infarct volume and the risk of bleeding in the brain. The ability 
of the combination therapy (fluoxetine and simvastatin) to improve motor recovery 
following stroke was estimated in both rehabilitated and non-rehabilitated female 10-12 
month rats. The combination of drugs and rehabilitation improved motor function recovery, 
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but ultimately, the same functional recovery was seen with the drugs when there was no 
rehabilitation, making this treatment potentially useful for stroke patients who cannot 
undergo rehabilitation. The Forelimb Asymmetry test for the motor function was refined 
so that it showed greater sensitivity and correlated better with results from the Montoya’s 
staircase grasping test.  Finally, the potential mechanisms by which the pharmacological 
treatment works to aid recovery were investigated, exploring any putative sex-specific 
pattern of gene expression in the peri-infarct region in male and female rats at post-stroke 
day 7. A preliminary genetic analysis along with protein-protein interaction prediction 
reveal a fundamental role of animal sex in the response to drug treatment. The study shows 
a variation in the influences of the drug on pro- and anti-inflammatory biomarkers of 
microglia, regulation of neurotrophic factors and synaptic plasticity, with a new possible 
role of a neuropeptide Orexin and receptors in mediating the functional recovery in male 
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1.1 Stroke and its Current Treatment 
 Stroke is a life-threatening medical condition that occurs when the normal blood 
supply to the brain is interrupted. There are two main types of strokes: ischemic, which 
happens when a thrombus or embolus blocks a cerebral artery supplying blood to the brain. 
This leads to deprivation of oxygen and nutrients to one area of the brain followed by 
cellular death in the affected area. The second type of stroke is hemorrhagic, which occurs 
when a weakened blood vessel ruptures and leaks either near the surface of the brain 
resulting in subarachnoid hemorrhage or into the tissue deep within the brain, as in 
intracerebral hemorrhage. In addition to these two forms of stroke, a transient ischemic 
attack (TIA), known as a mini-stroke, may occur as a short-term episode of transient 
neurologic dysfunction when the blood supply to part of the brain is briefly interrupted. 
The TIA is considered a warning sign of stroke risk.  
According to the American Heart Association, stroke is the fifth-leading cause of 
death in the United States (Mozaffarian et al., 2016). The majority of strokes, ~ 87%, are 
ischemic (Rosamond et al., 2008). In ischemic stroke, there is an immediate loss of neurons 
after the initial insult depends upon where the stroke was, resulting in permanent damage 
to the brain, and increasing the risk of long-lasting disabilities (Saver, 2006). Stroke can 
affect people of all ages and backgrounds. In the United States, every 40 seconds someone 
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has a stroke and, on average, every 4 minutes one American dies of a stroke (Mozaffarian 
et al., 2016). Approximately 800,000 strokes occur every year in the United States. 
Depending on the location of stroke and severity of the attack, patients may experience 
serious problems with speech, walking, seeing, and understanding. The condition can 
potentially be fatal if not timely treated. The estimated annual direct and indirect costs 
associated with stroke treatment in the United States was $71.55 billion in 2010 and that 
expected to double by 2030  (Mozaffarian et al., 2016).  
Ischemic stroke is a leading cause of the majority of long-term disabilities. One 
ongoing cardiovascular cohort study, the Framingham study, shows that survivors of an 
ischemic stroke who were at least 65 years of age experienced serious disabilities after 
stroke (Gore-Felton et al., 2003). Some of the limitations observed were muscular 
weakness on one side of the body, inability to walk, aphasia, depression, and dependence 
in daily living tasks.  
Intravenous thrombolysis with recombinant tissue plasminogen activators (rt-PA), 
such as alteplase, reteplase, and tenecteplase, are the only FDA-approved pharmacological 
therapies available for ischemic stroke. These clot buster medications are believed to be 
effective in breaking up blood clots if given within 3 to 4.5 hours after symptom onset 
("Tissue plasminogen activator for acute ischemic stroke. The National Institute of 
Neurological Disorders and Stroke rt-PA Stroke Study Group," 1995). However, a recent 
review indicated uncertainty for the short time window data; and recommended re-
evaluating the safety and efficacy of the treatment within that time window (Alper, 
Malone-Moses, McLellan, Prasad, & Manheimer, 2015) 
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Stroke sufferers arriving at a hospital outside of this therapeutic window may not 
be eligible to receive the therapy, as later application results in hemorrhagic transformation 
(Lees et al., 2010). Unfortunately, only a small percentage of stroke patients reach the 
hospital in time to be considered for the clot buster (Wahl & Schwab, 2014). Patients 
presenting within 48 hours of symptom onset are given the anti-coagulant agent, aspirin, 








Figure 1. Mechanism of action of recombinant t-PA (Adapted from (Chhabra, 2014) 
 
According to the guidelines from the American Heart Association/American Stroke 
Association for the initial management of patients with acute ischemic stroke, intravenous 
rt-PA (such as Alteplase) can only be given to a selected group of patients within a short 
time window of the onset of stroke symptoms (Del Zoppo, Saver, Jauch, Adams, & 
American Heart Association Stroke, 2009). Patient must be under 80 years of age, have no 
history of previous stroke or diabetes, not be taking any oral anticoagulant medications, or 
have an NIH Stroke Score greater than 25 (Adams et al., 2007). The National Institutes of 
Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers 
to objectively quantify the impairment caused by a stroke. The use of rt-PA in stroke 
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patients beyond that therapeutic time frame could lead to potential side effects such as 
bleeding complications and angioedema (Miller, Simpson, & Silver, 2011). Currently, less 
than 8.5% of patients are able to take the only available pharmacological treatment, rt-PA, 
within the required time after the onset of stroke symptoms (A. M. Corbett et al., 2015). 
This limitation has necessitated studies to come up with a more efficient treatment that is 
readily available and can be delayed over four and half hours. 
Even with the success of endovascular therapy, in which a clot is removed under 
direct angiographic visualization as in the MERCI retriever (Mechanical Embolus 
Removal in Cerebral Ischemia), intravenous rt-PA within the first 4.5 hours remains the 
standard of care. That is because not all patients are suitable candidates for MERCI 
retriever and sometimes even ideal candidates have major complications after a mechanical 
removal of the thrombus.  Endovascular therapy is for patients who have (NIHSS) ≥ 6 and 
demonstrated large occlusion in middle cerebral artery, internal carotid artery, or anterior 
cerebral artery on imaging. For these reasons, there is a pressing need to identify a 
pharmacological therapy that can safely be administered beyond that short time window 
for the majority of stroke patients.  
For fifteen years after rt-PA was approved, several experimental studies failed to 
translate their data into clinically useful neurorestorative therapies for acute ischemic 
stroke (Dirnagl, 2006). The majority of these preclinical studies were performed using 
rodent models of permanent or transient focal cerebral ischemia in which induction of 
middle cerebral artery occlusion (MCAo) is done by insertion of a surgical filament into 
the external carotid artery to block the middle cerebral artery at its origin (Longa, 
Weinstein, Carlson, & Cummins, 1989). This widely used model, however, is susceptible 
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to issues of anatomical accuracy and requires careful practice to avoid surgical 
complications, such as damage to adjacent tissues and bleeding. In addition, the MCAo 
model produces a larger infarct volume in animal brain and always have a higher mortality 
rate in aged rats, which limit the assessment of functional disabilities in adult animals after 
stroke (R. Y. Wang, Wang, & Yang, 2003).   
In 2011, a randomized, double-blind placebo-controlled trial called FLAME 
(Fluoxetine in Motor Recovery of Patients with Acute Ischemic Stroke) examined the 
influence of the anti-depressant selective serotonin reuptake inhibitor, fluoxetine, on 
functional motor recovery after acute ischemic stroke (Chollet et al., 2011). This study led 
to a fundamental change in ischemic stroke treatment and re-ignited hope that this drug 
could improve motor recovery and reduce post-stroke disabilities. Experimental studies in 
our lab have shown that administration of a drug combination consisting of the anti-
depressant fluoxetine and the cholesterol-lowering drug simvastatin in addition to L-
ascorbic acid (Vitamin C), in an adult rat model of ischemic stroke 20-26 hours after 
symptom onset, successfully improves motor recovery and reduces functional impairment 
in the rats. Furthermore, the drug combination significantly increased neurogenesis up to 
19-fold in treated animals versus controls (A. M. Corbett et al., 2015).  The underlying 
mechanisms by which this drug combination works to enhance functional motor recovery 
in stroke patients are not at all clear. Based on animal studies in our laboratory and others,  
there are some potential mechanisms whereby fluoxetine might augment functional 
recovery in ischemic brain. These include stimulation of neurogenesis, where a robust pool 
of newly generated neurons migrate to ischemic areas; stimulation of angiogenesis; 
regulation of neurotrophic factors; and synaptic plasticity (Siepmann et al., 2015).  
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A modified procedure to induce focal ischemic stroke by endothelin-1 (A. M. 
Corbett et al., 2015) was performed in these animals to produce relatively small infarcts 
compared to the widely used model of MCAo with a gradual injury perfusion similar to 
that in humans. A post-stroke drug combination of fluoxetine and simvastatin, in addition 
to L-ascorbic acid (FSA), was orally delivered in a stress-free environment to improve 
functional motor recovery after stroke and to complement the limited availability of the 
only available pharmacological therapy, tissue plasminogen activator (tPA) (A. M. Corbett 
et al., 2015).  
By reviewing pre-clinical studies on stroke, there are gaps in previous research that 
contributed to the unsuccessful translation. Some questions were asked: What would be the 
best animal model with biological similarities to the human brain that can efficiently 
simulate the pathological processes after ischemic stroke? How could we 
design appropriate methodologies to mimic the clinical situation closely? The lack of 
translation could not be entirely attributed to the choice of animal model, but also in how 
such models and their resultant data are applied (Howells et al., 2010).  
1.2 Problems with Translating Pre-Clinical Animal Studies to Human Clinical Trials 
Despite tremendous investments in advancing translational stroke research, many 
pre-clinical studies failed in translating their findings from animal studies into human 
clinical trials, thus have not been adopted into clinical practice. The main factors causing 
the failures of neuroprotective treatments have been explained in the STAIR (Stroke 
Therapy Academic Industry Roundtable) guidelines for preclinical stroke trials (Stroke 
Therapy Academic Industry, 1999).  The factors include inappropriate time windows of 
drug administration, ineffective dose, using medications that can not cross the blood-brain-
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barrier, the age of the animal is young, morbidities and mortalities in young animals, and 
the heterogeneity of stroke subtypes in patients. In addition to animal age, sex bias is 
another essential factor that should be considered when translating research from 
preclinical studies. Young male animals are usually employed in preclinical studies (Beery 
& Zucker, 2011). Some other explanations of this unsuccessful translation could be related 
to poor experimental design: lack of randomization or using inappropriate animal models 
that do not accurately mimic the disease condition in a human. An example of poor 
experimental design is choosing animal strains for particular study without taking into 
account the variation in their drug metabolism, which can lead to an unclear conclusion 
regarding the efficacy and toxicity of the medicine treatment. Moreover, not all animal 
models used for inducing focal ischemic stroke have brain blood vessel collateralization 
that mimics human cerebral vasculature. Also, using ineffective assessment methodologies 
along with inappropriate statistical analyses may contribute to the failure of research 
translation. The number of animals that are employed in the experimental studies is 
imperative, an inadequate statistical power when few animals are used, along with 
inaccurate statistical analyses can substantially influence results. A publication bias is 
another important factor contributing to this failure (S. Liu, 2009). Studies suggest that 
research directions of authors and reviewers (Joyce, Rabe-Hesketh, & Wessely, 1998), 
conflicts of interest (Perlis et al., 2005), research funding sources (Liss, 2006) are few 
examples of factors influencing publication bias. 
1.3 Randomization in Animal Studies 
A growing body of evidence is indicating that randomization and blinding outcome 
assessment in pre-clinical studies can minimize the potential risk of bias (Bath, Macleod, 
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& Green, 2009). Some of the key solutions to avoid any possible biases are random 
assignment of test animals to experimental and control groups without any prejudice. Being 
blinded to groups in functional assessments and when evaluation and analysis performed 
is vital. No information should be known to the observer who performs the analysis besides 
animal’s number. In our experiments, we have controlled for bias, and we have tried to be 
as objective as possible. In cases where there may be some subjectivity in the observation 
(e.g. examining whether only tips of fingers or palms of the hand are touching a wall in 
Forelimb Asymmetry tests), we typically use one observer to perform an entire series of 
evaluations, so the same bias is present throughout a study.  To confirm that a proposed 
change in methodology is reliable, we have multiple different observers use the same 
method and evaluate the results across the different monitors to determine the inherent 
variability due to subjectivity.  
1.4 Animal Models of Stroke and Age of Model 
Animal models are essential to preclinical stroke research. Due to the complexity 
of interactions in the brain vasculature during the stroke, there is no in vitro model that can 
properly mimic these complicated pathophysiological mechanisms in humans. We chose 
rats as rodents are one of the most relevant animal models used in stroke research (Casals 
et al., 2011). Rats have been employed in stroke research due to their close resemblance to 
cerebrovascular physiology and anatomy to human, and reproducibility of stroke damage 
(Ginsberg & Busto, 1989). Nevertheless, no single animal model can precisely represent 
the variables affecting ischemic stroke patients (Bacigaluppi, Comi, & Hermann, 2010). 
We previously have done multiple studies on different strains of rats such as: Fisher, Long-
Evans, Wister, and Sprague-Dawley, to determine which one would make a better model 
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of the medical situation in humans. The majority of stroke studies are conducted using 
young animals which might react differently to stroke injury by initiating spontaneous 
neurogenesis (Casals et al., 2011). A large number of preclinical studies on stroke use 2-
month-old animals (100 grams) with MCAo method of stroke induction for preclinical 
studies on ischemic stroke. In contrast to these studies, we utilized a group of 10-12-month-
old rats (400-600 grams) because they have more similarity to human patients, who in most 
cases are middle-aged or older. Also, neurogenesis typically decreases with age (Walter, 
Keiner, Witte, & Redecker, 2011), hence requiring the drugs to be tested under similar 
conditions in both rats and humans. In our lab, adult male and female Sprague-Dawley rats 
were favored over all other strains for their brain blood vessel collateral circulation 
resembles that in people and because of the animal age correlates with the middle-aged 
person in clinical trials. 
1.5 Sex-dependent Differences 
Increasing evidence suggests that an animal’s sex may influence the results of 
stroke studies by multiple mechanisms, therefore animal’s sex is a potentially informative 
consideration for the development of new pharmacological treatment for stroke. The 
effectiveness of the drug may vary depending on animal sex (K. Li et al., 1996). A study 
indicated that there are sex differences in rat and mouse brains; and that gonadal hormones 
modulate prostaglandins (PGE2) in brain. (Dean, Knutson, Krebs-Kraft, & McCarthy, 
2012). The PGE2 regulates the response to injury after stroke with female rats showing 
better outcomes than males to the same injury. An experimental study using MCAo models 
of stroke has demonstrated that female rats have a prominently reduced infarct volume 
compared with male rats, and ovariectomized rats have infarct volumes that are similar in 
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size to male rats (Alkayed et al., 1998). Female steroid hormone estradiol plays a role in 
this neuroprotective effect in rats. Studies showed that administration of exogenous 
estrogen decreases infarct volume size in both male and female rats (Toung, Traystman, & 
Hurn, 1998). An interesting study showed that the amount of hydrogen peroxide produced 
by macrophages from male mice is more than female animals, and causing more tissue 
damage than macrophages from females (Y. Chen & Johnson, 1993). A study on human 
granulosa-luteal cell culture demonstrates that high concentrations of estrogen inhibit the 
activity of the inflammatory interleukin-1 (IL-1). IL-1 is a highly inflammatory molecule 
released early in ischemic tissue, which activates many inflammatory processes through 
activation of T cells and induce expression of acute-phase proteins. IL-1 plays a role in the 
neuronal injury that occurs following stroke (Polan, Daniele, & Kuo, 1988).  
We examined the drug combination, FSA, in both male and female animals to 
explore possible sex-de pendent changes in response to treatment. The findings are 
presented in details in the results section. 
1.6 Post-Stroke Physical Rehabilitation  
One of the criticisms of stroke work in animal studies is that they do not include 
physical rehabilitation, whereas human stroke patients undergo some form of 
rehabilitation. Choosing the right animal model of rehabilitation is important when 
interpreting results. We used Sprague-Dawley rats for the similarities to the neurovascular 
branching and the limb movements of the human arm (Yamori, Horie, Handa, Sato, & 
Fukase, 1976) and (Whishaw et al., 2002). One rehabilitative method that encourages the 
use of impaired limb while constraint the unaffected limb called constraint-induced 
movement therapy (CIMT).  This technique was developed by Taub et al. (Taub, Uswatte, 
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Mark, & Morris, 2006). Studies showed that CIMT after stroke can improve functional 
reorganization and plasticity of the brain in the adult rats (Qu et al., 2015); and in stroke 
patients (Nijland, Kwakkel, Bakers, & van Wegen, 2011) and (Wittenberg et al., 2003).  
However, other studies showed that this technique of rehabilitation increases animal stress 
which decreases neurogenesis (Livingston-Thomas, Hume, Doucette, & Tasker, 2013) and 
(Yanagita, Amemiya, Suzuki, & Kita, 2007).  
We are one of few laboratories that examined whether post-stroke voluntary 
rehabilitation could enhance functional recovery in the impaired limb. Other studies used 
enriched environments to improve cognitive and social stimulation and enhance post-
stroke recovery following stroke (Biernaskie & Corbett, 2001) and (Janssen et al., 2010). 
Although these studies may contribute to our understanding of the mechanisms of 
neuroplasticity, the intensity of initiated rehabilitation might not be enough to produce the 
desired effect. We have tested the impact of physical rehabilitation at different intensities 
on recovery with and without drug treatment. The findings from our studies are interesting 
in that they mirror some observations about rehabilitation from human clinical trials when 
evaluating the intensity of physical rehabilitation, and show that our drug combination may 
work equally well without rehabilitation (see Results section on Physical Rehabilitation). 
 
1.7 Functional Tests in Animal Studies 
Measuring the level of impairment and the influence of post-stroke treatment on 
motor recovery in animal models relies heavily on the applied functional assessment 
methods. To improve the translation of experimental therapies into clinical trials, 
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appropriate methods of functional measurements should be used to assess what is in the 
real-life clinical setting (Macrae, 2011). Due to the range of deficits that accompany 
ischemic stroke, a diversity of sensitive functional tests is needed. The chosen tests should 
precisely reflect the extent of deficit after ischemic stroke, and demonstrate the level of 
recovery reached by treatment.   Different functional tests have been used in stroke research 
to assess deficits associated with ischemic stroke in rodent models. Table 1 and 2 show 
animal behavioral tests with a strong or weak resemblance to functional tests in human 
(Schaar, Brenneman, & Savitz, 2010). 
 
Table 1. Animal behavioral tests with a strong resemblance to human trials. 
Functional Test Function 
 
Forelimb Asymmetry Test Measures spontaneous forelimb use and placing deficits 
 
Montoya Staircase Test Assesses forelimb extension, grasping skills, side bias and 
independent use of forelimbs 
Grid Walking Measures sensorimotor function, motor coordination and 
placing deficits during locomotion 
Reaching Chamber  Measures skilled forepaw use and motor functioning 
 
Pasta Test Evaluates manual dexterity and fine motor skills 
 
Ladder Rung Walking test Measures stepping, placing and coordination 
 
Corner Test Evaluates sensorimotor and postural asymmetries 
 






Table 2. Animal behavioral tests with a less resemblance to human trials. 
Functional Test Function 
 
Ledged Tapered Beam Assesses hindlimb functioning 
 
Accelerated Rotarod Measures motor coordination and balance 
 
Adhesive Removal Assesses tactile responses and asymmetries 
 
Morris Water Maze Measures spatial learning and memory (humans use 
location cues to find places everyday but the test is not 
applicable to human) 
 
1.8 Methods for Post-Stroke Assessment of Motor Function in Clinical Trials 
To increase the odds of translation of results from pre-clinical animal studies to 
human clinical trials, only accurate and reliable behavioral tests that mimic functional tests 
in clinical trials should be performed. In clinical studies, there are different ways to 
measure motor function and independence in activities of daily living (ADLs). One of the 
major criticisms of pre-clinical stroke studies in animals is that the post-stroke functional 
tests bear no resemblance to standard functional tests given to human stroke patients. In 
the previous section, I have evaluated whether certain post-stroke functional tests bear any 
resemblance to clinical tests performed on post-stroke patients. In this section, I will give 
more detail about what the major stroke tests for humans entail. 
1.8.1 Modified Rankin Scale (mRS) 
The Modified Rankin Scale (mRS) is one of the most commonly used methods to 
measure recovery in human stroke patients (Rankin, 1957), (Bonita & Beaglehole, 1988). 
This test uses a questionnaire to assess patient functional status and the ability of the patient 
to perform everyday life tasks by asking simple questions to both patient and caregiver. 
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A free Modified Rankin Scale calculator called mRS-9Q is available online (Patel 
et al., 2012). One of the ADL tasks evaluated in the mRS pertains to the ability of the 
patient to grasp an object and move it. A parallel behavioral assessment in animals includes 
Montoya Staircase. In this assessment the ability of each animal to grasp and hold onto an 
object with either forepaw is quantified and analyzed in order to evaluate gross arm 
movement, hand clasping, and fine finger movement control. 
 
Table 3.  Modified Rankin Scale (mRS) (Rankin, 1957). 
 
Another assessment criterion in the mRS is the balance and strength of affected 
arm, and the ability of the patient to use hands to support the entire body weight when 
getting into and out of a chair. This test aims to recognize abnormal function and determine 
whether patients are getting back to their normal function by doing the daily activities or 
not. We utilize Forelimb Asymmetry analysis to evaluate animal functional recovery based 
on the animal use of full palm to support their body weight when they rear up and explore 
the cylinder wall (See Methods section). In our modified Forelimb Asymmetry analysis, 
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we define forelimb function by the placement of the whole palm on the wall of the cylinder 
that indicates its use for body support. We do not count a half touch (fingertip touch) as a 
sign of getting back to normal function but as an indicator of injury. 
1.8.2 Fugl-Meyer Assessment (FMA) 
 The Fugl-Meyer scale is used to evaluate and measure motor recovery in post-
stroke hemiplegic patients (Fugl-Meyer, Jaasko, Leyman, Olsson, & Steglind, 1975). It has 
been widely used in stroke patients. The test is designed to assess impairment in motor 
functioning, sensation, balance, joint range of motion and joint pain (See Appendix I for 
full protocol). Each is scored on a 3-point ordinal scale, in which 0 = cannot perform; 1 = 
performs partially and 2 = performs fully. The motor score ranges from 0 to 100 points, 
which indicate hemiplegia or normal motor performance, respectively. Out of 100 points, 
66 points are for the upper extremity. This includes forearm supination/pronation, wrist 
flexion/extension, and tennis ball grasping, grasping of a cylinder and finger flexion 
(Duncan et al., 1994).  
Table 4. Standard methods for post-stroke assessment of motor function and global 
disability. Information obtained from “Post-Stroke Rehabilitation: Assessment, 
Referral, and Patient Management Quick Reference Guide” by the US Agency for 
Health Care Policy and Research. 




Scale (mRS) for 
global disability  
 5 minutes Overall assessment of 
disability. 







(Fugl-Meyer et al., 
1975)  
30-40 minutes Excellent validity and 








Depending on the severity of the stroke and its location, both dexterity and 
coordination might be impaired on the contralateral side, and sometimes on the ipsilateral 
side if the deficit is bilateral. Upper limb reaching, grasping and withdrawing are natural 
movement skills organized by the cerebral motor cortex. Many neurons interact with spinal 
circuits to regulate these locomotor movements. Brain damage to the motor cortex often 
impairs the contralateral arm and can affect these movements.  
An experiment by Whishaw et al. (See Figure 2) evaluated rat forelimb reaching 
using a comparative scale to that used to evaluate human performance (Whishaw, 
Whishaw, & Gorny, 2008). Each forelimb reach was divided into ten movements that were 
rated on a 3-point scale. Damage to the motor cortex, basal ganglia, brainstem, and spinal 
cord alters these movements (Leisman, Braun-Benjamin, & Melillo, 2014). Disruption of 
corticospinal connections leads to impairment of skilled finger, hand and arm movements. 
One common post-stroke motor deficit is impairment in fine motor movement and 
extension of the fingers (Trombly, Radomski, Trexel, & Burnet-Smith, 2002), however, 
the mechanisms of this weakening are not well understood. A comparative analysis that 
was performed on 21 species, including rats, indicates a similar role of the corticospinal 
tract in the evolution of digital dexterity among all examined species (Heffner & Masterton, 
1983). Therefore, rehabilitation that improves fine motor control and digit strength would 
greatly enhance the lives of stroke patients. Here we examine rat forearm extension/reach, 
(Montoya Staircase using advance, pronation, and grasping; and Forelimb Asymmetry 
using touching and stabilizing) in order to evaluate the potential benefit of drug therapy or 
























Figure 2. Similarities of hand shaping movements and position of the digits and wrist 
in rat and human subjects during a reaching movement. Adapted from (Sacrey, 




1.9 Neurogenesis after Stroke 
In order to develop an effective treatment for stroke, the acute and chronic events 
that are involved in ischemic stroke, as well as the associated mechanisms, must be clearly 
understood (Hossmann, 2006). One of the devastating effects of stroke is the loss of the 
neuronal circuitries, which support cognitive and sensory-motor capacities, due to neuronal 
cell death and dysfunction. This could lead to severe disabilities. During the first 3-6 
months following a stroke, patients might be able to regain some neurological abilities, but 
a majority of patients stay impaired to a critical degree (Duncan, Jorgensen, & Wade, 
2000).  It is now known that when an individual experiences a stroke, the brain sends 
signals to stem cell populations to divide and to move immature neurons to areas of damage 
in a process of neurogenesis. This process is most active during embryonic development. 
It was believed that adult brain is a physiologically static organ incapable of regeneration; 
however, neurogenesis has been shown to continue in two locations in the adult brain: the 
subventricular zone (SVZ) of the lateral ventricles, and the subgranular zone (SGZ), 
forming part of the dentate gyrus (DG) of the hippocampus (Barlow & Targum, 2007).  A 
resident population of neural stem/progenitor cells can provide a source of new neurons 
(Elder, De Gasperi, & Gama Sosa, 2006). 
After ischemic insult, recruitment of neural precursor cells from the major stem cell 
niches within the subventricular zone (SVZ) and the subgranular zone (SGZ) of the dentate 
gyrus into the damaged area are imperative compensatory responses in ischemic brain 
(Arvidsson, Collin, Kirik, Kokaia, & Lindvall, 2002). Neuronal proliferation within the 
subventricular zone has been shown to peak between 7 and ten days followed by a decline 
in proliferation activity during three weeks post-stroke (Parent, Vexler, Gong, Derugin, & 
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Ferriero, 2002). However, this therapeutic response is insufficient to support a full recovery 
after stroke due to the limited survival of newly formed neuroblasts that migrate to the 
damaged area.  
 
Figure 3: Intrinsic programs and external factors controlling adult neurogenesis. 
Adapted from (Lledo, Alonso, & Grubb, 2006). 
 
Stroke incidence triggers neurogenesis by stimulating neural progenitor cells of the 
SVZ to divide and migrate to the peri-infarct area (Arvidsson et al., 2002).  It is possible 
that radial microglia are involved with guiding migration of neuroblasts to the ischemic 
brain tissue (Cao et al., 2013).  There is evidence that neurogenesis is linked to angiogenesis 
(Ohab & Carmichael, 2008), which is a process of forming new blood vessels to enhance 
vascularization of the surviving neuronal cells (Greenberg & Jin, 2005).  For up to four 
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months of brain damage, neuroblasts are continuously produced in neurogenic areas 
including the subventricular zone (SVZ) leading to a pool of cells that can develop into 
fully grown neurons (Thored et al., 2007).  On the other hand, neurogenesis is inhibited by 
inflammation that occurs during stroke recovery (Jakubs et al., 2006). Neuronal, glial, and 
endothelial progenitor cells release growth factors that support synaptic plasticity of 
surviving neurons (J. Chen et al., 2005).  
 
1.10 Drugs Used for our Studies 
In an attempt to boost the recovery of ischemic brain, we tested a combination 
therapy of two FDA-approved drugs as a potential delayed post-stroke treatment. These 
include simvastatin (Zocor) and fluoxetine (Prozac), in addition to L-ascorbic acid 
(Vitamin C). The drug combination showed an increase in anterior subventricular 
neurogenesis and neurotrophic factors in both male and female animal models of ischemic 
stroke, as well as enhanced neuronal survival and plasticity (A. M. Corbett et al., 2015). 
Some studies examining fluoxetine’s effect on neurogenesis employed a synthetic 
nucleoside, bromodeoxyuridine (BrdU), to determine whether the brain is undergoing 
neurogenesis (Malberg, Eisch, Nestler, & Duman, 2000). These studies, however, are only 
evaluating the posterior sub-ventricular zone in the same slices as those of the dentate 
gyrus. The fact that this area is more caudally located than the previously examined area 
may explain why these studies did not highlight any effect of fluoxetine on neurogenesis.  
Fluoxetine is widely prescribed to treat depression and other mood disorders by blocking 
the presynaptic reuptake of serotonin. Simvastatin is a cholesterol-lowering drug that 
belongs to a group of drugs called HMG CoA reductase inhibitors. Vitamin C (L-ascorbic 
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acid) is an anti-oxidant that is added to the mixture to enhance the effect of the 
antidepressant and because of the serotonin sensitivity to oxidation. Statins have been 
shown to up-regulate the brain-derived neurotrophic factor (BDNF), which is a member of 
neurotrophic factors that mostly participate in nervous system development. The 
mechanism by which statins influence the BDNF up-regulation is mediated by an 
endothelial nitric-oxide synthase (eNOS) enzyme. Vitamin C enhances the catalytic 
activity of this enzyme through an unclear mechanism(s) (Huang, Vita, Venema, & 
Keaney, 2000). Each drug was chosen to contribute unique mechanisms when combined 
in the mixture to improve outcomes. Neurogenesis and BDNF are believed to be involved 
in the recovery of function following stroke. 
The initial experiments on this drug combination were conducted on Westar male 
sham stroke rats that received different combinations of fluoxetine, simvastatin, and L-
ascorbic acid to assess the impact of drug combination on neurogenesis versus controls. A 
mix of the three drugs significantly increased neurogenesis nineteen times compared to 
either the control or simvastatin and ascorbic acid.  Fluoxetine alone producing a 10-fold 
increase in neurogenesis, approximately half of that seen with the drug combination (A. 
M. Corbett et al., 2015). A combination of low dose (0.5 mg/kg) simvastatin and 20 mg/kg 
L-ascorbic acid treatment showed no increase in neurogenesis over controls. However, 
when both were added to 5 mg/kg fluoxetine, neurogenesis nearly doubled over that when 
using fluoxetine alone in male sham-operated rats. The combination of drugs produced a 
synergistic effect rather than additive.  Both simvastatin and fluoxetine are FDA-approved 
drugs that have been around for many years, so there is ample information on the 
pharmacokinetics, metabolites, and elimination of each.  
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Evaluation of the fluoxetine, simvastatin, and ascorbic acid compared to fluoxetine 
and ascorbic acid tested in functional recovery of female Long Evans rats post-stroke 
suggested that simvastatin and fluoxetine are both crucial to the most effective drug 
combination, though currently, it is not clear whether the L-ascorbic acid is essential in 
female rats. In these experiments, combining fluoxetine with L-ascorbic acid showed no 
increased functional recovery over fluoxetine alone in female rats after stroke induction. 
Whereas the addition of both simvastatin and L-ascorbic acid to fluoxetine showed 
approximately 2-fold increase over fluoxetine alone in functional recovery, which 
paralleled nicely the increase in neurogenesis that we observed in the subventricular zone. 
Taken together, this suggests that both fluoxetine and simvastatin are the key players to 
increasing neurogenesis and functional recovery over fluoxetine alone.  Studies that have 
used rats to evaluate BDNF production after ischemic stroke have shown BDNF expression 
to rise for a limited time (eight days after a stroke) (Kokaia, Andsberg, Yan, & Lindvall, 
1998), (Bejot et al., 2011). However, our delayed drug treatment (fluoxetine in addition to 
L-ascorbic acid) increased BDNF expression near the peri-infarct area 31 days after stroke. 
 
1.10.1 Fluoxetine  
Racemic fluoxetine ( N-methyl-3-phenyl-3-[4- (trifluoromethyl) phenoxy]propan-
1-amine), also known by trade name Prozac, is a selective serotonin reuptake inhibitor 
(SSRI) that was approved by the FDA for use in clinical practice since 2000. It is used to 
treat major depression and other mood disorders such as panic disorder, obsessive–
compulsive disorder (OCD) and bulimia nervosa. Fluoxetine crosses the blood–brain 
barrier (Warren, 2012), and studies showed fluoxetine to increase the expression of BDNF, 
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which plays a role in neurogenesis (Schabitz et al., 2007) and enhances cognition in 







Figure 4. Chemical structure of fluoxetine 
 
1.10.2 Pharmacokinetics of Fluoxetine  
Fluoxetine binds with high affinity to plasma proteins such as albumin and α1-
glycoprotein, and is metabolized in the liver by isoenzymes of the cytochrome P450 system 
(CYP2D6) to its active metabolite norfluoxetine (Alfaro, Lam, Simpson, & Ereshefsky, 
2000). Plasma concentrations of fluoxetine and its metabolite, norfluoxetine, peak in 6 to 
8 hours after oral administration. Using high-performance liquid chromatography (HPLC) 
method, we were able to detect fluoxetine and norfluoxetine in brain homogenate after 
seven days of single dose oral administration (A. Corbett, McGowin, Sieber, Flannery, & 
Sibbitt, 2012). Pharmacokinetic studies in rats show that distribution of the drug into tissues 
is similar to that in humans with faster elimination time in rats (4-7 hrs) (Benfield, Heel, & 
Lewis, 1986). In our study, the plasma levels of fluoxetine and norfluoxetine were 
detectable within 2 to 4 hours of ingestion, but not after 24 hours.  
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The elimination rate of fluoxetine and norfluoxetine in human is slow compared to 
other antidepressants due to the ability of drugs to inhibit their metabolism mediator 
(CYP2D6). Thus elimination half-life ranges from 1-3 days, after a single dose, to 4-6 days, 
after long-term use (Ouellet et al., 1998). The brain to plasma ratio of fluoxetine in patients 
is 2.6:1 (Strauss, Layton, Hayes, & Dager, 1997) . 
Numerous experimental studies have raised as many questions as they provide 
answers about the efficiency of fluoxetine in treating post-stroke deficits. Some of these 
studies showed SSRIs (fluoxetine in particular) as an active agent in producing functional 
recovery after focal brain injury in rat models (Windle & Corbett, 2005).  Few pre-clinical 
studies showed fluoxetine effectiveness on infarct size and demonstrated a potent 
neuroprotective action of the drug through its anti-inflammatory action on microglia (Lim 
et al., 2009). Moreover, fluoxetine has been shown to improve ischemia-induced spatial 
cognitive deficits in rats through increasing hippocampal neurogenesis after stroke (W. L. 
Li et al., 2009).  
Although many previous studies provided convincing evidence that selective 
serotonin reuptake inhibitors (SRRIs) are useful in the recovery process in animal models 
of stroke, the drug can have varying effects on neurogenesis and overall recovery based on 
animal age and sex. Moreover, the timing of drug administration is a paramount factor; an 
appropriate therapeutic time window should be established in animal models. Also, the 
method of drug administration has a significant influence on the outcome, as stress would 
antagonize the effects of fluoxetine on the brain (Balch et al., 2015).   
The FLAME clinical trial (Fluoxetine in Motor Recovery of Patients with Acute 
Ischemic Stroke), which was published in 2011 in THE LANCET neuro has shown that 
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the anti-depressant fluoxetine could help repair the damage caused by stroke and improve 
functional motor recovery in patients. The study was conducted in ischemic stroke patients 
with hemiparesis at nine stroke centers in France. A total of 113 stroke patients from 
different stroke centers across France were enrolled in the trial and randomized to 
fluoxetine (N = 57) or placebo (N= 56) groups for 90 days. Fluoxetine (Prozac) 20 mg/day 
or placebo was delivered for three months starting five to ten days after stroke onset. 
Following the FLAME trial, most of the stroke studies that examined SSRIs’ effects on 
motor recovery have been conducted using fluoxetine more than other SSRIs, such as 
citalopram, sertraline, paroxetine, and escitalopram (Mead et al., 2013).  
In this trial, the primary outcome was mean change in the Fugl-Meyer Motor Scale 
(FMMS) between baseline (day 0) and day 90. Secondary endpoints were assessed by the 
NIH Stroke Scale (NIHSS) and modified Rankin Scale (mRS). All patients included in this 
study were aged 18-85 years. The mean age of patients was 66.4 years in the fluoxetine 
group and 62.9 years in the placebo group. The study reported that at three months, 15 
(26%) of acute stroke patients who received fluoxetine and 5 (9%) of patients allocated to 
placebo had a modified Rankin score (mRS) between 0 and 2, which means they can 
perform daily activities with no dependency on other people.  
Some ongoing large-scale trials have continued to examine the effectiveness of 
fluoxetine when given 2-15 days following stroke onset. These include the AFFINITY 
(Assessment of Fluoxetine in stroke recovery) trial in Australia, the FOCUS (Fluoxetine 
or control under supervision) trial in the United Kingdom, and the EFFECTS (Efficacy of 
Fluoxetine – a randomized controlled trial in stroke) in Sweden (Mead et al., 2013). 
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 The promising results of the FLAME clinical trial provided clear evidence of the 
role of fluoxetine in stroke recovery independently of depression when given to ischemic 
stroke patients. However, the mechanisms involved in recovery from stroke or dementia 
are not entirely understood (Dam et al., 1996).  
Fluoxetine has neuroprotective properties that may be associated with its anti-
inflammatory effects (D. Liu et al., 2011). A recently published study suggested a 
neuroprotective role of fluoxetine in ischemic stroke through changing inflammatory 
activated microglia into a neuroprotective activated microglia in a process called microglia 
polarization (Su, Yi, Xu, & Zhang, 2015). The study was conducted in vitro on both 
primary microglia cells and murine microglial cell line (BV-2) and demonstrated that 
fluoxetine significantly down-regulates the gene expression and protein production of pro-
inflammatory mediators (M1 activation indexes) while up-regulating the M2 activation 
indexes (neurotrophins, Stat 3, Stat 6, arginase expression) in both cell line and primary 
cells. Nonetheless, in vitro studies do not necessarily correlate with in vivo efficacy. A 
study in a rat cerebral ischemia model of middle cerebral artery occlusion indicated an anti-
inflammatory role of fluoxetine through suppression of microglial activation and 
neutrophil infiltration (Lim et al., 2009). To assess these findings, we developed our 
customized PCR arrays (Custom RT2 PCR Array from Qiagen) with 38 genes of interest 
that have been shown to be differentially expressed in inflammation in response to 
activation of different types of microglia. Most pharmacological studies have been 
conducted using a racemic form of fluoxetine, however, increasing evidence indicates that 
the enantiomers of racemic drugs often differ markedly in their pharmacodynamic and 
kinetic properties (Williams & Lee, 1985). We tested the anti-inflammatory effects of 
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racemic fluoxetine and compared the effects of its enantiomers (R (-)-fluoxetine and S (+)-
fluoxetine) on microglia activation using the RT2 PCR Array technique to profile microglia 








Figure 5. The (R)-enantiomer and the (S)-enantiomer of fluoxetine 
 
 In addition to its beneficial effect on neurogenesis, fluoxetine also influences 
angiogenesis by stimulating expression of vascular endothelial growth factor (VEGF), one 
of the main neurotrophic factors that mediate angiogenesis as well as neurogenesis and 
neuroprotection following ischemic stroke.  This upregulation suggests a broad role of 
fluoxetine in brain recovery after stroke (Gaillard & Mir, 2011). Preclinical findings in 
aged mice also showed that fluoxetine induces a rise in serum concentrations of VEGF 
(Kubera et al., 2009). We tested the effect of fluoxetine on neurotrophins, its receptors, and 







Simvastatin (also known by trade name Zocor) is a cholesterol-lowering medication 
that belongs to the class of drugs known as statins.  Simvastatin is used mainly to treat 
dyslipidemia and prevent stroke and heart attacks in high-risk individuals. It has beneficial 
effects on coronary diseases (Alberts, 1990), and usually is used to reduce the risk of 
cardiovascular morbidity and mortality ("Randomised trial of cholesterol lowering in 4444 









Figure 6. Chemical structure of simvastatin 
 
1.10.4 Pharmacokinetics of Simvastatin 
After an oral dose, simvastatin is quickly absorbed and metabolized from its 
inactive lactone prodrug form into pharmacologically active metabolite (simvastatin β-
hydroxy acid), which acts by inhibiting the enzyme 3-hydroxy-3-methylglutaryl-
coenzyme-A (HMG-CoA) reductase (Gotto, 1997). The HMG-CoA is a rate-limiting 
enzyme of the metabolic pathway responsible for the biosynthesis of cholesterol (Pedersen, 
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2010). Simvastatin undergoes extensive first-pass metabolism in the liver. The drug can 
cross blood-brain-barrier. The bioavailability of simvastatin after oral administration is 5% 
(about 95% is excreted), with peak plasma concentrations reached at 4 hours.  
Simvastatin is known to enhance endothelial function, inhibit a thrombogenic 
response and reduce oxidative stress and inflammation (Liao & Laufs, 2005). Also, statins 
have been shown to provide neuroprotection against ischemic injury. The mechanisms by 
which statins provide neuroprotection are not clearly understood. However, some studies 
suggest statin action through upregulating of endogenous tissue plasminogen activator 
(Asahi et al., 2005), and restoring endothelial nitric oxide synthase (eNOS) activity during 
hypoxia. This enzyme generates nitric oxide in blood vessels that is involved with 
regulating vascular function and neurogenesis (Estrada & Murillo-Carretero, 2005; 
Hernandez-Perera et al., 1998; Laufs, Fata, & Liao, 1997). Others proposed a beneficial 
role of statins through inhibiting inflammatory response and platelet aggregation (Sanchez 
et al., 2008). Statins have also been shown to stimulate neurogenesis and angiogenesis, and 
to promote new synapses formation (Rodriguez-Yanez, Agulla, Rodriguez-Gonzalez, 
Sobrino, & Castillo, 2008).   
 Statin treatment has been shown to reduce the incidence of ischemic stroke among 
people who are at high risk of cardiovascular diseases, and therefore it is recommended for 
use in stroke patients to prevent recurrent stroke (Tuttolomondo et al., 2013). In addition 
to their role in ischemic stroke, statins promote neurovascular recovery after hemorrhagic 
stroke (Yang, Han, Zhang, Chopp, & Seyfried, 2012). 
Due to its lipophilic nature (Thelen et al., 2006), simvastatin can readily cross the 
blood-brain barrier and passively diffuse across the endothelial cells allowing more 
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widespread tissue distribution (Wood, Eckert, Igbavboa, & Muller, 2010).  Moreover, 
studies have found that simvastatin upregulates growth factors such as brain-derived 
neurotrophic factor (BDNF) and Vascular endothelial growth factor (VEGF), which are 
important in promoting neurogenesis and angiogenesis (Yang et al., 2012), (Wu et al., 
2008). Simvastatin also reduces the infarct volume after ischemic stroke (Zacco et al., 
2003) and has the potential to protect against neuronal excitotoxicity caused by 
overstimulation of glutamate receptors during an ischemic injury (Zhu et al., 2012). Recent 
rodent studies suggest a beneficial role of statins when combined with tPA in extending 
the therapeutic window for tPA as the combination drug improved thrombolysis of clot at 
the MCA occlusion site (L. Zhang, Zhang, & Chopp, 2012). Information from pooled data 
of stroke patients showed the effect of dose-related simvastatin/tPA combination on the 
outcome after tPA thrombolysis for ischemic stroke. The study noticed an association 
between the dosage of simvastatin (20mg, 40mg, and 80mg) and increased risk of 
intracerebral hemorrhagic transformation ( 2%, 6% and 13%, respectively) (Scheitz et al., 
2014). Optimizing the dose of statins when combined with tPA is crucial to extend the 
therapeutic window for tPA (Lapchak & Han, 2010). So far there is only one trial that 
investigated the effect of pre-treatment with statins on brain injury in cerebral ischemia and 
showed a beneficial effect of statin on reducing brain injury after stroke (Blanco et al., 
2007). The study also looked at the influence of statin withdrawal on the outcome of acute 
ischemic stroke patients and recommended that statin should be continued in the acute 
phase of ischemic stroke because the withdrawal was associated with increased risk of 




1.10.5 Ascorbic Acid (Vitamin C) 
Vitamin C or L-ascorbic acid is a potent reducing agent and effective antioxidant 
that protects against the potential damage caused by free radicals to lipid membrane and 





Figure 7. Chemical structure of ascorbic acid (Vitamin C) 
Vitamin C can cross the blood–brain barrier in the oxidized form. This passage is 
mediated by BBB glucose transporters (Agus et al., 1997). A study of tissue distribution of 
vitamin C that calculated the concentration of radiolabeled ascorbic acid in mice showed 
up to 3 fold increase of ascorbic acid in the brain compared to the blood concentration 
(Hornig, 1975). Multiple studies have demonstrated that consumption of vitamin C rich 
food can lower the risk of stroke (G. C. Chen, Lu, Pang, & Liu, 2013). However, the 
findings are still inconclusive and need further investigation to understand the different 
effects of dietary vitamin C and circulating vitamin C on the risk of stroke (Rabadi & 
Kristal, 2007). As vitamin C is water soluble and tends to be quickly absorbed and excreted 
from the body, it might be beneficial to use the slow-release (extended) formulation of 
vitamin C rather than the plain-release form. As one study indicates that there are 
pharmacokinetic differences between plain and slow release formulations of ascorbic acid 
(Viscovich, Lykkesfeldt, & Poulsen, 2004). 
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Our Experimental  
Rat Dose 
Human equivalent 
Fluoxetine 20 mg/day 5 mg/kg  40 mg/day 
Simvastatin 10-20 mg/day 1 mg/kg 8 mg/day 
Vitamin C 500 mg/day 20 mg/kg 160 mg/day 
 
 
1.11 Drug Delivery Method in Animal Studies 
The most common routes of drug administration in laboratory animals are using 
oral delivery through forced feeding tube passed into the stomach (gavage), subcutaneous, 
intraperitoneal or intravenous injection. All of these methods of drug delivery are highly 
stressful for animals, as they involve some restraint, which is a major stressor for rodents.  
Distress due to physical restriction and morbidity are some of the common adverse 
reactions associated with these procedures, and they can negatively influence the outcome. 
Because stress can adversely affect neurogenesis (Sahay & Hen, 2007), and many 
physiological processes such as glucose metabolism, body temperature and cerebral blood 
flow (Meijer, Spruijt, van Zutphen, & Baumans, 2006), it is crucial to minimize the 
unnecessary stress during drug delivery by using a reliable method of voluntary drug 
administration. A study on rats that underwent gavage procedure indicates that a 32% 
mortality rate was attributable to granulomatous inflammation or asphyxia caused by 
impacted food and bedding material in the oropharynx (Germann & Ockert, 1994). Our 
laboratory sought to eliminate these unwanted effects by developing a technique for 
voluntary oral drug administration to rats using premixed drug-cookie dough balls (A. 
Corbett et al., 2012). In our method, we incorporate the drug combination in a powder form 
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with 4 gram of sugar cookie dough and present it to the animal in a glass dish at the same 
time every day. This method allows for more drug delivery to the bloodstream than the 
gavage method due to drug absorption through lingual and buccal membranes. The 
voluntary oral ingestion of a drug resulted in reduced level of the stress hormone 
(corticosterone) in male rats when compared to a subcutaneous injection of the same drug 
(Goldkuhl, Carlsson, Hau, & Abelson, 2008). 
 
1.12 Possible Drug Mechanism of Action  
 To understand the mechanisms by which the drug combination (FSA) works to 
induce motor function, I consider potential pathways that might be involved in drug action. 
These include: 
 
1.12.1 Modulation of the Blood-Brain-Barrier Permeability 
 The Blood-brain-barrier (BBB) consists of a network of elements consisting of 
brain endothelial cells connected by tight junctions, a basement membrane, pericytes and 
astrocyte feet forming an interface between the brain and circulatory system (Hawkins, 
O'Kane, Simpson, & Vina, 2006). The blood-brain-barrier has a high selective permeability 
that separates the circulating blood from the brain extracellular fluid and allows the passage 
of molecules that are essential to neural function while it protects the brain from exposure 
to harmful molecules.  After ischemic insult to the brain, impairment of the blood-brain-
barrier integrity is a central event of the pathophysiology, in which the ischemic structural 
damage causes abnormal leaks across the blood-brain-barrier (del Zoppo & Hallenbeck, 
2000). Also, endothelial cells of the BBB upregulate the expression of matrix 
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metalloproteases (MMPs) activation, which is a family of enzymes responsible for 
degrading the extracellular matrix proteins, and protease-activated receptor 1 (PAR1) in 
the ischemic area (Rosell & Lo, 2008). The pericytes are also involved in microvascular 
dysfunction after stroke through constricting the obstructed vessel (Yemisci et al., 2009). 
Furthermore, stroke downregulates the expression of a cell surface molecule, beta-1 
integrin, which is essential for endothelial cell adhesion and migration during angiogenesis 
resulting in increased BBB permeability (del Zoppo & Milner, 2006). 
 A recent study indicates that fluoxetine suppresses matrix metalloproteases 
(MMPs) activation in adult male mice after spinal cord injury (J. Y. Lee, Kim, Choi, Oh, 
& Yune, 2012). This inhibitory action prevents disruption of blood-brain-barrier after 
spinal cord injury.  
To investigate the effect of fluoxetine and its enantiomers (R (-)-fluoxetine and S 
(+)-fluoxetine) on blood-brain barrier, we used a method for determining BBB integrity 
based on intracardiac perfusion of an Evans Blue (EB) dye. Brain tissue homogenates from 
the cerebral cortex and the cerebellum were examined in each male and female rat to 
measure the amount of fluorescence that indicates the EB concentration. We noticed a 
significant difference in the BBB permeability in both cortex and cerebellum when both 
male and female rats treated with S-fluoxetine were compared to male rats treated with R-
fluoxetine. Animals that received S-fluoxetine enantiomer treatment showed less BBB 
permeability than the ones treated with R-fluoxetine. However, the change was not 
significant among the female R- fluoxetine and S-fluoxetine groups when compared to 
each other. One possible explanation of this action is that S-fluoxetine is more efficient in 
inhibiting the breakdown of the tight junctions that connect endothelial cells of the BBB. 
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  1.12.2 Upregulation of Neurotrophins or their Receptors 
 Some of the potential targets of ischemic stroke treatments are growth factors, 
particularly those that have been shown to get involved in promoting neural regeneration 
and angiogenesis, as well as inhibiting the neurotoxicity and inflammatory process within 
ischemic penumbra. Neurotrophins are a family of growth factors that prevent neuronal 
damage and promote neuronal survival and repair (Y. Zhang, Zhang, Katiella, & Huang, 
2014). Administration of neurotrophins in experimental animals have shown to correlate 
with functional motor recovery after stroke. The potential benefit to human health that 
would come from a better understanding of the regulation of neurotrophins and their 
receptors after stroke cannot be overstated.  
Studies have demonstrated that brain is not a static organ, and damage to the adult 
brain can induce the formation of new neurons, in a process of neurogenesis that continues 
throughout life (Eriksson et al., 1998). This injury-induced neurogenesis is augmented by 
different types of growth factors that eventually lead to efficient brain repair and recovery 
of function. In the first stages of ischemia, regenerative mechanisms in the brain are 
activated in the first few hours (Rickhag et al., 2006), followed by reduced tissue edema, 
some repair of injured neurons, activation of neuronal pathways and migration of 
neuroblasts and glial cells into the area around infarct, known as the penumbra (Marlier, 
Verteneuil, Vandenbosch, & Malgrange, 2015). The process is accompanied by 
angiogenesis in the peri-infarct zone. In surviving tissue, activation of both growth 
promoting and inhibiting factors occurs, but full recovery is limited due to the limited 
capacity for the anatomical reorganization of the brain (Carmichael, 2005). Reactivation 
of existing neural pathways after stroke insult seems to be one of the cellular responses 
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involved in functional recovery. Other strategies include combining of new neural 
pathways following neurogenesis (Wieloch & Nikolich, 2006). Over the past several years, 
many experimental studies aimed at stimulating functional recovery during the first weeks 
after stroke have proposed different therapeutic strategies. The plans include activating 
brain plasticity, changing the housing environment to an enriched environment as well as 
adding training and physical rehabilitation (Biernaskie & Corbett, 2001). Animal studies 
reported that post-ischemic administration of growth factors such as vascular endothelial 
growth factor (VEGF) (Z. G. Zhang et al., 2000), brain-derived neurotrophic factor 
(BDNF) (Schabitz et al., 2004) , epidermal growth factor (EGF) (Teramoto, Qiu, Plumier, 
& Moskowitz, 2003), Heparin-binding epidermal growth factor-like growth factor (HB-
EGF) (Jin et al., 2004), nerve growth factor (NGF) (Dahlqvist et al., 1999), Insulin-like 
growth factor-1 (IGF-1) (X. F. Liu, Fawcett, Thorne, DeFor, & Frey, 2001; X. F. Liu, 
Fawcett, Thorne, & Frey, 2001), erythropoietin (EPO) (Leist et al., 2004), stem cell factor 
(SCF) (Schneider et al., 2005) and granulocyte colony-stimulating factor (GCSF) (Kawada 
et al., 2006) can stimulate angiogenesis, promote neurogenesis, reduce infarct volume and 
improve recovery in animal models of ischemic stroke. Some studies showed that improved 
environment can upregulate growth factors such as nerve growth factor (NGF) and enhance 
recovery (Dahlqvist et al., 1999), others focused on the role of some growth factors in 
promoting recovery of function. For example; blockade of basic fibroblast growth factor 
(bFGF) in ischemic rats reduces motor recovery (Rowntree & Kolb, 1997). Based on their 
role in angiogenesis and neurogenesis, we proposed neuroprotective properties of 




1.12.3 Orexin Receptor Upregulation 
 Orexin is a neuropeptide regulator of appetite, sleep and glucose metabolism. There 
are two types of orexins known as orexin-A and orexin-B, also called hypocretin-1 (HCRT-
1) and hypocretin-2 (HCRT-2) (Sakurai et al., 1998). Orexins mediate their action through 
activating two G-protein-coupled receptors, orexin receptor 1 (OXR1) and orexin receptor 
2 (OXR2), that are expressed in the brain (Trivedi, Yu, MacNeil, Van der Ploeg, & Guan, 
1998). The activation of orexin receptors excites orexin neurons and promotes the release 
of presynaptic glutamate (Yamanaka, Tabuchi, Tsunematsu, Fukazawa, & Tominaga, 
2010). Orexin is associated with neuronal cell apoptosis and autoimmune function (de 
Lecea et al., 1998). Some animal studies have recently shown that orexin-A exerts 
neuroprotective effects by increasing the Hypoxia-inducible factor-1 activity and reducing 
the oxidative stress in rats (Yuan et al., 2011). Orexin also plays a major role in modulating 
the inflammatory response in ischemic brain injury (Song, Kim, Kim, Song, & Lee, 2015), 
a study showed that orexin controls inflammation by regulating pro-inflammatory 
cytokines such as the IL-6 and TNF-α in microglia and protecting the neurons against 
oxidative stress caused by cerebral ischemia (Xiong et al., 2013). Also, two separate studies 
in rats (Kitamura et al., 2010) and mice (Harada, Fujita-Hamabe, & Tokuyama, 2011) 
indicated that intracerebroventricular injection of orexin-A into the animal brain before 
stroke surgery reduced infarct size. Furthermore, studies reveal that orexins play a positive 
role in stimulating hippocampal neurogenesis (Kim et al., 2010), and increasing the 
expression of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) in 




1.12.4 Changes in Microglial Activation 
Besides the neuronal loss and cognitive dysfunction after stroke, inflammation of 
the central nervous system is one of the pathological processes resulting from ischemic 
stroke. Microglia, the resident macrophage of the CNS and the primary immune cells that 
contribute to neuroinflammation, is an integral component of the inflammatory immune 
response in the brain. There has been much debate regarding the precise origin of 
microglial progenitors. Studies suggest that microglia arise from peripheral mesodermal 
tissue in the yolk sac. Like macrophages, activation of microglia leads to multiple activities 
including antigen presentation, phagocytosis, cytokine production and the release of matrix 
metalloproteinases that deteriorate the blood brain barrier and cause peripheral leukocyte 
infiltration  (Iadecola & Anrather, 2011). Stimulation of microglia with various signals can 
drive a range of different inflammatory or anti-inflammatory responses in a process called 
microglia polarization as shown in Figure 8.  
Emerging evidence indicates that microglia polarization is involved in many types 
of central nervous system injuries including stroke (Hu et al., 2012). Activated microglia 
can be polarized into two main opposing phenotypes: cytotoxic pro-inflammatory 
phenotype M1, and neuroprotective, anti-inflammatory phenotype M2; which can be 
further subdivided into M2a, M2b, and M2c (Mantovani et al., 2004). Targeting the 
polarization mechanism to drive microglia from detrimental phenotype to beneficial 
phenotype could help in protecting brain tissue from further damage and resolve 
inflammation. Although immunosuppression might be an effective strategy in 
counteracting the inflammatory response to ischemic injury, a complete inhibition of the 
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inflammatory process without an increase in neurotrophic factors may worsen the outcome 
















Figure 8. Microglia polarization into a range of functional phenotypes: pro-
inflammatory M1 and anti-inflammatory M2 phenotypes. M2 microglia has three 
subsets; M2a, M2b, and M2c based on stimulating pathway (upper panel).  Molecular 
markers of all phenotypes are categorized in the table as follow: (1.) signaling 
molecules, (2.) cytokines, (3.) chemokines, (4.) scavenger receptor expression and (5.) 





Three hypotheses were proposed:  
1) That earlier delivery of the combination drug would result in smaller infarct size, 
and a closer examination of the wall touches in Forelimb Asymmetry test may allow us to 
refine the analysis and get similar contralateral deficits to Montoya Staircase. 
 2) That post-stroke physical rehabilitation can boost motor recovery when 
combined with the combination drug therapy. 
 3) That the drug combination exerts sex-dependent neuroprotective effects by 
modulating microglia activities from pro-inflammatory to anti-inflammatory.  
 
1.14 Specific Aims 
 
Specific Aim I   
A). To examine whether administering the combination drug at an earlier time point 
after the onset of stroke symptoms would reduce infarct volume. 
B). To improve the sensitivity of the Forelimb Asymmetry test by refining wall 
touches into a more specified parameter that correlates better with functional tests 
from Montoya staircase. 
 
Specific Aim II 
To investigate the impact of moderate rehabilitation with the impaired arm on 
functional recovery with and without post-stroke drug treatment. 
 
Specific Aim III 
To explore sex-dependent changes in gene expression of inflammation and 
polarization markers expressed by microglia in the peri-infarct zone in response to 
combination drug treatment. Neurotrophic factors and synaptic plasticity genes will also 









MATERIALS AND METHODS 
 
We used 10-12-month-old male Sprague-Dawley rats (generally 450-500 grams) to 
accomplish our specific aims 1 and part of specific aim 3. We compared our results with 
those from previous work in our lab in which 10-12-month-old female Sprague-Dawley 
rats were used for sex-dependent changes in gene expression.   Female Sprague-Dawley 
rats were used in specific aim 2, where we evaluated the effect of rehabilitation on 
functional recovery with and without drug treatment.  All animals are obtained from Harlan 
Laboratories (Indianapolis, IN) and fed Harlan rat chow. Animal experiments are approved 
by the Institutional Animal Care and Use Committee at Wright State University, and 
procedures followed are in accordance with institutional guidelines. 
 
2.1 Surgery for Stroke Induction 
All animals underwent endothelin-1-induced stroke procedure using the 
vasoconstrictive peptide ET-1 (Sigma, St. Louis, MO, USA). The procedure is based on 
modifications to Windle’s protocol (Windle et al., 2006).  Anesthesia was induced with 5% 
isoflurane, and the animals were maintained on 2-2.5% isoflurane using an anesthesia mask 
on the stereotactic apparatus (Stoelting Co., USA). A micro-drill was used to drill two close 
holes in the skull using two different set of coordinates relative to bregma to hit the forelimb 
motor cortex. It is critical to determine the location of stroke induction precisely to assure 
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destroying the forelimb motor cortex itself rather than the tissues surrounding it. Bregma 
position can be determined by looking at fusion lines on the skull surface where the coronal 
suture meets the sagittal suture. The basic surgical procedures are described in a previous 
study (A. M. Corbett et al., 2015), with the following modifications: two holes are drilled 
in the skull, with positions relative to bregma of (0.0 mm A.P., 2.5 mm M.L.) and (1.5 mm 
A.P., and 2.5 mm M.L.).  The procedure starts with cleaning the surgical area using 
proviodine-iodine solution, followed by 70% ethanol then proviodine-iodine solution 
again. At the top of the animal head, a midline incision is made, and bupivacaine (0.25%) 
is administered to the incision to provide local analgesia for 12 hours. A 0.9 mm burr 
micro-drill is used to drill two holes in the skull (Fine Science Tools, Foster City, CA). A 
needle containing endothelin-1 was inserted into both holes in the skull, then lowered to a 
depth of 2 mm.  One and one-half microliters of endothelin-1 (600 pmols) was injected 
into each hole over a period of 5 minutes. After that, the incision site was sutured and 
painted with a povidone-iodine solution to prevent infection. To avoid adverse effects of 
analgesics on neurogenesis (Hoehn, Palmer, & Steinberg, 2005), (Sargeant, Miller, & Day, 
2008), no post-operative analgesics besides bupivacaine were used. 
Endothelin-1 induced stroke surgery has advantages over the most commonly used 
ischemic stroke induction, the Middle Cerebral Artery Occlusion (MCAo). The ET-1 
induced operation produces about 5% of ischemia in the cortex, which is similar to the 
majority of human strokes, compared to 45-50% injury seen in a single hemisphere in the 
MCAo, stroke model. It has a gradual reperfusion that closely mimics reperfusion in stroke 
patients (Mecca, O'Connor, Katovich, & Sumners, 2009). In addition to that, the large 
damage caused by blocking the middle cerebral artery and other arterial openings before 
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the middle cerebral artery can cause feeding difficulties in the animal and damage to the 
hypothalamus (Dittmar, Spruss, Schuierer, & Horn, 2003). This damage can affect drug 
intake and negatively influence the study outcomes. The intraluminal suture method of 
Middle Cerebral Artery occlusion (MCAo) has a high mortality rate in old animals. We 
had a smaller mortality rate in older experimental animals (under 10%) using ET-1 induced 
stroke model, which makes this technique a valuable model for basic and translational 




























Figure 9. Schematic of a rat skull depicting the position of injection holes in 





2.2 Voluntary Oral Administration of the Drug 
Our method involves putting the drug in a 4-gram ball of purchased Pillsbury® 
sugar cookie dough.  The cookie dough was weighed, rounded into a ball and then a 
depression pushed into the ball with a finger. The individually-weighed drugs 
(Pharmaceutical grade crushed tablets or contents of capsules) were put into the depression 
in the dough ball, and rim edges of the depression were brought together and sealed so that 
all the dry chemicals were enclosed in the dough ball. The dough ball was thoroughly 
mixed manually to incorporate all of the chemicals into the dough and reformed into a ball.  
The ball is presented to the animal in a glass dish at the same time every day and placed in 
an animal cage overnight to allow complete ingestion. Control animals receive the 4-gram 













Figure 10. Voluntary Oral Administration of the Drugs. A. Drug incorporation into 
4 gm of cookie dough; B. Rat is voluntarily consuming medication at the same time 




2.3 Functional Tests  
       2.3.1 Montoya Staircase Test  
Montoya staircase assesses grasping motor function, a motor function that often 
show deficits following stroke, which is responsible for many stroke patients’ disabilities 
in everyday living. Thus, functional improvements in this motor function in rat models of 
stroke should translate well into clinical trials, which would test the same function. Rats 
are fasted overnight and then placed on a restricted diet consisting of 85% of their ad 
libitum rat chow while they are trained to pick up sucrose pellets, painted with maple 
extract, on the Montoya staircase (Montoya, Campbell-Hope, Pemberton, & Dunnett, 
1991).  The Montoya staircase consists of a raised platform with seven stairwells on each 
side containing sucrose pellets (three per stairwell), allowing left and right forelimb 
function to be independently assessed.  Painting the sucrose pellets with maple extract or 
using chocolate flavored sucrose pellets is important during the training phase to entice rats 
through their sense of smell to reach down the sides of the platform and pick up the sucrose 
pellets, as they have a limited downward vision in this apparatus.    
Rats must be properly trained before surgery for dependable post-operative data. 
Training occurred during the dark-phase consisting of 15-minute trials inside the Montoya 
staircase. Training lasts anywhere from 10-14 days.  At the end of the training period, the 
rat’s pre-stroke performance is determined by the best overall performance (highest total 
number of pellets retrieved) during the last three days of training.  The majority of animals 
learn to retrieve between 15-18 pellets with each of their paws.  
On post-stroke day 3-5, the rats are tested on the Montoya staircase again, and their 
best performance is used as a measure of their post-stroke baseline performance.  To 
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normalize their performance, we divide the number of pellets taken by each paw post-
stroke by the number of pellets retrieved by each paw pre-stroke.  Thus, when the quotient 
is 1, the animal had fully regained pre-stroke function in a particular limb, and when the 
quotient is less than 1, that means the animal has a functional deficit in that limb.  Animals 
that failed to reach training criteria, retrieving at least nine pellets with the left paw, on 




Figure 11. A rat on a central platform in the Montoya staircase box is reaching for 








     2.3.2 Forelimb Asymmetry Test (Cylinder test)  
The animal is placed in a transparent vertical cylinder and videotaped for 5 minutes. 
Rats would rear up and touch the walls of the cylinder with their right and left forepaws to 
explore their environment.  Normally before stroke induction, the majority of rats show 
little preference for the right or left paw during this exploration behavior. However, when 
rats were tested again on post-stroke day 4, they usually show a preference for touching 
the wall with their ipsilateral (right) paw, while they held their left paw back toward their 
body.  Typically in this analysis, we look at the percentage of touches to the wall by right 
or left paw post-stroke and divide that by their pre-stroke performance percentages. 
However, since I am aiming to improve the sensitivity of the test, wall touches were refined 
into palm touches versus fingertips and palm touches to determine which of these correlate 













Figure 12. A Sprague-Dawley rat is rearing up against the cylinder wall and exploring 
the arena.  Both paws show full palm touches. Adapted from (Schallert, Fleming, 
Leasure, Tillerson, & Bland, 2000) 
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2.4 Exclusions   
All animals that underwent stroke and displayed less than 20% baseline 
contralateral deficit in the Montoya staircase are excluded from the Specific Aim 1 (Part 
B) since we didn’t have a Montoya Staircase functional analysis to compare with the 
Forelimb Asymmetry test. Animals must have learned to pick up at least nine pellets with 
at least their left forepaw or they are excluded from the Montoya staircase analysis. Any 
animal failing entirely to ingest post-stroke daily medicine or vehicle for a total of 3 days 
is completely excluded from the study: no animal was excluded for this reason in my work. 
During stroke induction surgery, movement of the needle through the cortex sometimes 
nicks a blood vessel and causes some bleeding, if a surgical artifact generates substantial 
bleeding, the animal is not included in the study: there were none excluded on this criterion 
in the study.  When infarct volume is measured, a rat brain is excluded from the analysis if 
the brain was damaged either during dissection or the cryostat sectioning, such that we 
could not mount the individual slices or could not accurately determine the entire infarct 
volume. One animal was excluded based on this criterion (Rat 855 from the 6-12 hours 
treatment group).  
2.5 Physical Rehabilitation Procedure 
Recovery after ischemic stroke is a complicated process that occurs through a 
combination of restoration and compensation of functions as a response to both 
pharmacologic and physical therapies. In addition to drug treatment, post-stroke physical 
rehabilitation has been considered essential for enhancing functional motor recovery in 
stroke patients. Studies indicate that rehabilitation induces brain plasticity after stroke 
(Kleim, Jones, & Schallert, 2003), with an evidence of promoting neuroplasticity by 
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increasing BDNF production (Mang, Campbell, Ross, & Boyd, 2013). Another study 
shows that post-surgical rehabilitation sessions in rats that require the use of both 
forelimbs; therefore force the animal to use the impaired forelimb, can stimulate the BDNF 
production in the brain leading to improved functional motor recovery (Livingston-
Thomas, McGuire, Doucette, & Tasker, 2014).  
We examined whether post-stroke physical rehabilitation could improve functional 
motor recovery in drug-treated versus vehicle-treated rats (Ragas et al., 2015). Our lab 
designed a hanging rack to hold peanut butter just outside of an opening in the rat’s cage 
(Figure 13).  Because of the position of the shelf, the rat is only able to reach it with the 
contralateral paw (left paw) to the infarcted right hemisphere.  The shelf was hung every 
other night with approximately 1-2 grams of peanut butter beginning eight days post-stroke 
and continuing for an overall period of five and half weeks.  All other animals began to eat 
from the shelves within three days. Using this observation, we were able to determine if 
the animal underwent rehabilitation or not. We saw no difference in the number of 
completely-cleared versus partially-cleared shelves between the drug groups. This method 
enabled physical rehabilitation of the contralateral limb without the stress of physical 
restraint of the ipsilateral limb. 
 Rehabilitation was begun on post-stroke day 8 and continued every other day until 
post-stroke day 45. During rehabilitation, the hanging shelves were loaded with 1-2 grams 
of peanut butter and hung around 5:00 pm each day. The shelves were collected 24 hours 
later and evaluated for whether the animal used its impaired paw. Animals generally began 





























Figure 13. Voluntary Physical Rehabilitation. (A). Hanging shelf for rat 
rehabilitation.  (B). the animal has not eaten from the shelf. (C). the animal has 
partially eaten from the shelf.  (D). the animal has completely cleared the shelf of all 















2.6 Preparing Tissues for Immunohistochemistry (IHC) Experiment 
Rats were injected with sodium pentobarbital (Euthasol; 100 mg/kg, i.p.) and 
returned to their cages to allow them to obtain a surgical plane of anesthesia. Animals were 
then perfused through the left ventricle of the heart using 100 ml of phosphate buffered 
solution (PBS) followed by 150 ml of 4% paraformaldehyde in PBS as a fixative.  A blunt-
edged cannula was used to deliver solutions through a small incision in the ventricle, to 
ensure it did not cross the interventricular septum. After 15-20 minutes of fixation, brains 
were removed and placed in the same fixative solution overnight at 4°C then immersed in 
30% sucrose solution for three days at the same temperature. After that, brain tissues were 
stored at −80°C until use. Coronal sections of 50μm starting anterior to the infarct site were 
sliced on a cryostat at −25°C. Each slice was immersed into one of six vials, containing 
PBS, which is labeled according to the type of proposed experiment. The infarct analysis 
vials were labeled as 1:500 8-OHdG (8-hydroxy-deoxyguanosine antibody) and Control; 
the other four vials were used for other projects in our lab using different staining 
techniques such as H&E and Prussian blue. 
Immunohistochemistry staining was performed on free-floating coronal sections in 
the 8-OHdG vial. The sections were incubated overnight at 4°C with a primary antibody 
(1:500 dilution of mouse monoclonal antibody against 8-OHdG, Abcam) to detect the 
nucleic acids damage by oxidative stress. Sections were then treated with horse radish 
peroxidase biotinylated secondary antibodies (donkey anti-mouse antibodies). Sections 
then rinsed twice with PBS-Tween and immunoreactivity was visualized by the Avidin-
Biotin Complex method using VIP as a substrate for the horse-radish peroxidase (VIP 
impact kit; Vector Laboratories). Coronal slices from 8-OHdg vials and Control vials were 
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carefully mounted on microscope slides using a paintbrush and set aside to dry. Slides were 
cover slipped using DPX mountant. 
2.7 Infarct Measurement  
Brightfield images were taken of the sections using a 4X objective, then montaged 
using advanced panoramic image stitcher called Image Composite Editor (ICE) into a 
complete picture of a damaged region of the brain as indicated by a dark staining (infarct).  
Area of the infarct was determined with ImageJ (Fiji open source software) from NIH.  
Infarct area (mm2) was determined for every sixth slice, then multiplied by the slice 
thickness (0.05 mm) and 6 to determine the complete infarct volume in mm3.  
Table 6 presents an example of infarct measurement in which the infarct volume 
was determined from 16 coronal brain sections collected from one animal. Slides were 
numbered as they were assessed for the presence of infarcts and sections on the slide were 
numbered left to right.  Area of infarct was determined with Image J software, after setting 
the scale.  The multiplier number varied from experiment to experiment, and in this case 
merely indicates that one out of every six brain coronal slices were used to measure infarcts 
volume with 8-OHdG.  The final summed volume of the infarct for this animal is shown in 




















Multiplier Volume Final 
volume 
mm3 
860 1 1 1.517 0.05 6 0.4551  
860 1 2 1.131 0.05 6 0.3393  
860 1 3 1.297 0.05 6 0.3891  
860 1 4 1.897 0.05 6 0.5691  
860 2 1 2.272 0.05 6 0.6816  
860 2 2 1.661 0.05 6 0.4983  
860 2 3 1.546 0.05 6 0.4638  
860 2 4 1.089 0.05 6 0.3267  
860 3 1 1.745 0.05 6 0.5235  
860 3 2 1.581 0.05 6 0.4743  
860 3 3 1.694 0.05 6 0.5082  
860 3 4 1.613 0.05 6 0.4839  
860 4 1 1.24 0.05 6 0.372  
860 4 2 1.608 0.05 6 0.4824  
860 4 3 1.128 0.05 6 0.3384  











2.8 Preparing Samples for Genetic Analysis 
 After injecting animals with sodium pentobarbital (Euthasol; 100 mg/kg, i.p.), 
animals were injected with a 1ml of Evans Blue dye directly into the ventricles of the heart 
and then perfused with PBS to clear the dye. The brain is dissected, blocked and then the 
coronal portion containing the infarct dropped into a beaker containing isopentane and dry 
ice to freeze tissues for cryosectioning.  The frozen coronal block is kept at -80 °C in a 
scintillation vial until the cut on the cryostat.  On the cryostat, tissue was cut from the 
anterior-most end until the infarct was reached.  An RNAseZap® cleaned microtome blade 
and forceps were then used to remove a block of tissue surrounding the infarct. The blocks 
of tissue ranged from 20-30mg in weight, are placed into pre-weighed RNase and DNase 
free plastic vials for the tissue homogenization step. To isolate RNA, 600 µl of lysis buffer 
(Qiagen RNeasy RLT Plus) were added to disrupt the tissue using a conventional rotor–
stator homogenizer until it is uniformly homogeneous ( about 30 seconds).  Next, the lysate 
was centrifuged at maximum speed for 3 minutes and the supernatant was carefully 
transferred into a new microcentrifuge tube. Then, 600 µl of 70% ethanol were added to 
the cleared lysate and mixed well. A   700 µl of the sample was transferred to an RNeasy 
spin column placed in a 2 ml collection tube and centrifuged at 8,000 x g for 30 seconds. 
The flow-through volume was discarded. Next, 700 µl of a wash buffer RW1 was added 
to the RNeasy spin column and centrifuged at 8,000 x g for 30 seconds. The flow-through 
volume was discarded. A 500 µl of Qiagen RPE wash buffer was added to the RNeasy spin 
column and centrifuged at 8,000 x g for 30 seconds. After discarding the flow-through 
volume, this step was repeated with centrifugation time of 2 min. The RNeasy spin column 
was placed into a 2 ml collection tube and centrifuged at 16,000 x g for 1 minute to further 
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dry the membrane, then placed into a 1.5 ml collection tube. Forty microliters of RNase-
free were directly added into the spin column and centrifuged at 8,000 x g for 1 minute to 
elute the RNA. The concentration of the purified RNA was determined using a NanoDrop 
spectrophotometer and the RNA samples were stored at -80 degrees Celsius for future 
analysis. 
2.9 Gene Expression Analysis Using Real-Time PCR 
RT2 PCR Array technique is a reliable tool for analyzing the expression of different 
genes allowing us to detect genes of interest accurately by probing with cDNA, reversed 
transcribed from the mRNA in the peri-infarct regions of rat brain using Qiagen First 
Strand Kit.  Both the mRNA purification kit and reverse transcription kit have a genomic 
DNA elimination step to remove any false positive signals that might develop as a result 
of contamination in RNA samples. Other quality control elements implanted within the 
array are: housekeeping genes for data normalization, reverse-transcription controls (RTC) 
for the efficiency of the first strand cDNA synthesis, and positive PCR controls to test PCR 
performance. Each well has a replica on the PCR 96-well plate to assess the reproducibility 
and validity of the data. Results from each sample and its replica are averaged before 
running the online data analysis which automatically performs all ΔΔCt based fold-change 
calculations.  Average Ct values for all gene replicates were calculated first, then delta Ct 
value between the gene of interest and housekeeping gene for each experiment were 
calculated. Delta-delta Ct values obtained from delta Ct experiment – delta Ct control.  
A comprehensive gene expression profile for different gene pathways can be 
carried out in less than 6 hours using three different Qiagen kits. Animal’s tissue is first 
homogenized using a rotor-stator homogenizer to prepare tissue for the RNA purification. 
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The second step is to purify RNA using a spin-column method (the Qiagen Universal 
RNeasy Mini Kit). RNA was converted to complementary DNA (cDNA) by performing a 
reverse transcription using the First Strand Kits (contains a step for the elimination of 
genomic DNA). The genomic DNA elimination mix was prepared according to the RT2 
First Strand protocol and processed through a gradient thermal cycler. The next step was 
to mix the cDNA with the ready-to-use RT2 SYBR® Green qPCR Mastermix and RNAse 
free water; this mixture is then aliquoted (25 µl per well) across the RT2 Profiler Array. 
The real-time PCR cycling program runs on the ABI 7900HT thermocycler for 40 cycles, 
using absolute quantification.  
Figures 15, 16 and 17 demonstrate custom RT2 PCR array layouts for M1 and M2 
microglia biomarkers, RT2 Profiler synaptic plasticity PCR array and for neurotrophic 
genes and their receptors array, respectively. The complete lists of gene symbols, 








































Figure 15. Custom RT2 PCR Array layout for M1/M2 Microglia Biomarkers.  Light 
blue wells each contain a real-time PCR primer sets for the indicated 
inflammatory/microglia activation related genes. All wells from column 1 to 6 are 
replicated in columns 7 to 12. Dark blue wells contain a housekeeping gene panel to 
normalize array data (Ppih, Actb, Hprt1, Ldha and Nono). Red wells H2 and H8 
contain genomic DNA controls (GDC). Wells H3, H4, H9, and H10 include replicate 
reverse-transcription controls (RTC). Wells H5, H6, H11, and H12 include replicate 









Figure 16. The diagram illustrates the layout of the 84 different primers for rat 
synaptic plasticity genes, controls for reaction quality (genomic DNA contamination, 











Figure 17. The diagram shows the layout of the 84 different primers for neurotrophic 
genes and their receptors, controls for reaction quality (genomic DNA contamination, 





2.10 Protein-Protein Interaction (PPI) Database 
To investigate the relationships between the up-regulated and down-regulated 
genes and the physiological significance of the interactions among them, I utilized the 
Search Tool for the Retrieval of Interacting Genes (STRING) version 10.0 to predict 
interaction information with high-confidence. The resource is accessible online at 
http://string-db.org. STRING is a comprehensive database that provides a computational 
prediction of protein-protein functional and physical associations. It is one of the widely 
used PPI databases that contain interaction networks from a wide variety of organisms. 
Adjustable confidence scores (low, medium or high confidence) are provided to each of 
the interactions in STRING, in addition to information on protein domains, 3D structures, 
and interactive network viewer that cluster networks on demand. All information can be 
obtained by searching for multiple proteins by names or identifiers in the program search 
engine and selecting the organism type (Rattus norvegicus strain in this study).  
The current version (v10.0) of STRING database covers more than 9.6 million 
proteins from over 2000 organisms ranging from Bacteria, Archaea to Homo sapiens 
(Szklarczyk et al., 2011; Szklarczyk et al., 2015). STRING imports information from 
various sources, including digitized experimental data from scientists and publications 
such as PubMed and FlyBase (Wodak, Pu, Vlasblom, & Seraphin, 2009).  
To investigate potential interactions within the genes, upregulated and down-
regulated genes were considered as two separate groups. If two or more genes were 
identified in both the groups, they were fed into the STRING database identifier for 





Figure 18. Screenshot of protein-protein network from the STRING website. Network 
can be rearranged and clustered directly in the browser window revealing tightly 
connected functional molecules with their role in different pathways. The thickness 
of lines between nodes is a rough indicator of the strength of the association. Large 





2.12. Research Plans 
In the first part of this study, we are examining the influence of the timing of 
administration of fluoxetine after stroke onset on the final infarct size and the risk of 
developing secondary hemorrhagic transformation.  Since the majority of stroke patients 
coming into the hospital are already on statins due to dyslipidemia, the experiment more 
closely modeled clinical trials by starting all animals on 1 mg/kg simvastatin seven day 
pre-stroke and continuing daily. Interesting findings in our laboratory on the effect of early 
drug delivery on infarct size in female rats have prompted us to investigate the relationship 
between the timing of drug administration and infarct size in male rats. Daily 5 mg/kg 
fluoxetine and 20 mg/kg ascorbic acid administration were begun at three initiation time 
points (6-12 hours post-stroke, 20-26 hours post-stroke and 48-54 hours post-stroke) in rats 
that pre-treated with simvastatin for one week.  
We also sought to improve the sensitivity of one of the behavioral tests for the 
motor function: the forelimb asymmetry test. Traditionally during this test, the animal is 
placed in a clear vertical tube and videotaped for 5 minutes. The number of times the animal 
touches the wall with its right or left paw is quantified using slow motion video analysis.  
For pre-stroke animals, we usually see around a 50:50 use of the right and left forepaw. 
After the stroke surgery, we see more use of the ipsilateral paw (right paw) with inhibition 
in the utilization of the left paw.  This test takes a long time to complete the analysis, as 
the number of wall touches must be quantified for each fore-paw, but it is a test that does 
not require any training so that it could apply to all animals in the study.  The manner in 
which we are counting wall touches (any touch to the wall) seems to lower the sensitivity 
of the test to the deficit produced.  We have noticed that following a stroke; the animal 
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tends not to put full weight on the left paw (does not flatten the palm against the wall). This 
behavioral test is important in that it can be applied to every rat, yet with our current method 
of analysis (any touch to the wall counts), it does not correlate well with functional deficits 
observed with the Montoya staircase test (which shows finer motor control deficits). A 
more precise approach has been proposed to evaluate another method for counting wall 
touches (differentiating between a full palm touch and a fingertip touch) to see if the full 
palm touches better correlates with results from the Montoya staircase test.  
The second goal of this study is to determine whether physical rehabilitation might 
enhance functional motor recovery in drug-treated rats versus control animals. Post-stroke 
physical rehabilitation has been considered essential for enhancing functional motor 
recovery (Faralli, Bigoni, Mauro, Rossi, & Carulli, 2013). Clinical studies suggest that 
early rehabilitation therapy after stroke may improve physical function, increase brain 
plasticity and improve the skills needed to perform activities (Feigenson, McDowell, 
Meese, McCarthy, & Greenberg, 1977) and (Hayes & Carroll, 1986). A recent study on 
the effects of post-stroke rehabilitation on recovery in MCAo model rat indicates that daily 
rehabilitation enhances functional outcome (Sasaki et al., 2016). The degree of impairment 
produced in human patients after stroke differs from experimental dysfunction in rats based 
on stroke inducing procedure. The majority of acute stroke patients show severe 
impairment or total loss in upper extremity movement, while rats show a little deficit of 
forelimb movement in the MCAo model of focal ischemia (Kleim, Boychuk, & Adkins, 
2007) . Also, the severity of rehabilitation, time of the procedure and the influence of stress 
are essential factors that influence the outcome. Some of the stroke studies on rats utilized 
intensive rehabilitation protocol in which the intact forelimb is constrained after the stroke 
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induction surgery to force the animal to overuse the impaired forelimb for movement and 
body support (Risedal, Zeng, & Johansson, 1999), (Bland et al., 2000). This type of 
stressful rehabilitation led to reduced functional recovery. Since physical rehabilitation in 
stroke patients involves assistance from the therapist in contrast to animal rehabilitation, 
which is totally hands-off, it is crucial to choose the right rehabilitation task in rat models 
to ensure that task is successful. Our method of rehabilitation using a hanging shelf filled 
with peanut butter accomplished rehabilitation of the impaired limb without restraint thus 
reduced stress during rehabilitation.   
Finally, a newly discovered neuroprotective role of fluoxetine in suppressing 
microglia-mediated inflammation in vitro (Su et al., 2015) has directed us to investigate 
the genetic mechanisms for this inhibitory role aiming to explore other potential influences 
of fluoxetine on modulating microglial polarization from pro-inflammatory (M1) 
phenotype towards beneficial anti-inflammatory (M2) phenotype. In conjunction with 
previous work in our laboratory that showed fluoxetine stimulates neurotrophic factors and 
synaptic plasticity in female rats, in this study, the effects of fluoxetine on the neurotrophic 


























3.1 Specific Aim I   
 
3.1.1 To examine whether administering the combination drug at an earlier time point after 
the onset of stroke symptoms would reduce infarct volume. 
 
Our previous experiments had indicated that administration of fluoxetine and 
simvastatin at 20-26 hours post-stroke decreases the volume of ischemic infarcts in 
Sprague-Dawley female rats (10-12 months old) (Balch et al., 2015). This current 
experiment is more closely modeled on current clinical trials by starting all animals on 
simvastatin 7 days pre-stroke and continuing daily in male Sprague-Dawley rats. The 
purpose of this experiment is to determine the impact of the time to treatment of fluoxetine, 
in combination with simvastatin, on the infarct volume and the risk of secondary 
hemorrhagic transformation. Daily 5 mg/kg fluoxetine and 20 mg/kg ascorbic acid 
administration were begun at three initiation time points (6-12 hours post-stroke, 20-26 
hours post-stroke and 48-54 hours post-stroke). We included the 48-54 hour time-point 
because this is the earliest time point used in three ongoing clinical trials (FOCUS, 
AFFINITY, EFFECTS) testing fluoxetine effects on motor recovery post-stroke. Animals 
were randomly assigned to either drug or control group after the surgery, but before the 
baseline stroke deficit was determined using either Montoya Staircase or Forelimb 
Asymmetry tests.  After drug treatment had been begun, it was continued daily until post-
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stroke day 7. All animals were euthanized on post-stroke day 7, so we could see any 
evidence of hemorrhagic transformation. Infarct volume was assessed at post-stroke day 
seven by immunohistochemical determination of 8-hydroxy-2'deoxyguanosine (8-OHdG), 
which locates nuclei that are under oxidative stress, using ImageJ software.  
 
Table 7. Male treatment groups with different times of drug delivery.  All groups were 
given 1 mg/kg simvastatin beginning 7 days before stroke induction and continuing 
through PSD 7.  Column 2 shows any daily drug treatment for that group, with any 
fluoxetine and ascorbic acid administration beginning at the times indicated in 
Column 1, and continued daily until the euthanasia time-point (Column 5).  
Functional tests were administered at the times indicated in Columns 3 and 4. 
 





 Control  (N=9) 1 mg/kg simvastatin  PSD 3-5 PSD 4 PSD 7 
6-12 hrs. FSA  
(N=11) 
5 mg/kg fluoxetine  + 1 mg/kg 
simvastatin +20 mg/kg 
ascorbic acid 
PSD 3-5 PSD 4 PSD 7 
20-26 hrs. FSA  
(N=9) 
5 mg/kg fluoxetine  + 1 mg/kg 
simvastatin + 20 mg/kg 
ascorbic acid 
PSD 3-5 PSD 4 PSD 7 
48-54 hrs. FSA 
(N=10) 
5 mg/kg fluoxetine  + 1 mg/kg 
simvastatin +20 mg/kg 
ascorbic acid 



















Figure 19. Representative images showing 8-OHdG staining of the infarct area 
indicative of oxidative DNA damage. A. This panel shows significant reduction of 
infarct volume when fluoxetine and the ascorbic acid combination was administered 
20-26 hours after stroke surgery in simvastatin pre-treated rats.  B. Infarct size in 
early drug delivery animal (6-12 hours after stroke induction) is similar to Control 






In this experiment, all male Sprague-Dawley rats were on 1mg/kg simvastatin for 
seven days before stroke induction and continued for seven days post-stroke, then were 
euthanized. Typically, control animals had 5-13 mm3 infarct volume following endothelin-
1 induced stroke, when stained with 8-OHdG primary antibody (Abcam; see figure 19 for 
representative images from the 20-26 hour administration (Panel A) versus early drug 
delivery (Panel B). In the control group (see Table 8, Figure 19 and Figure 20), the mean 
infarct volume was 8.035 ± 0.6418 mm3 SEM (N=10). Animals that received fluoxetine 
and ascorbic acid beginning 6-12 hours after stroke induction showed no significant 
difference in infarct volume compared to control (7.626 ± 1.009 mm3 SEM, N=11); 
however, when fluoxetine delivered 20-26 hours post-stroke that resulted in significant 
reduction (p=0.0366) of infarct volume (4.782 ± 0.8845 mm3 SEM, N=9). Interestingly, if 
the delivery of fluoxetine was delayed to 48 hours following stroke induction, the infarct 
size showed no significant change in comparison to control 8.202 ± 0.8754 mm3 SEM 
(N=9).    
Furthermore, brain sections in the delayed treatment group (48-54hrs) showed 
evidence of hemorrhagic transformation in the peri-infarct area when stained with H&E 
(see Figure 21).  In figure 21, the dark blue staining was examined by pathologist Smita 
Krishnamurthy, M.D. and she confirmed that the extensive staining in panels A, B, and D 
is due to peripheral macrophage and lymphocyte infiltration, while panel C shows very 
little infiltration.  This fits in with our previous idea that we may be eliminating reperfusion 
injury in this group of animals:  24 hours after stroke is when reperfusion would generally 
be predicted to occur in this endothelin stroked rat. Administering the drug at this time 
point appears to stop the reperfusion in compare to delaying treatment to 48 hours. To 
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examine the probability of hemorrhagic transformation occurring in drug groups to the 
probability of the event occurring in control group, an MD/Masters student in the lab, Neal 
Verma, analyzed the relative risk of hemorrhagic transformation in these groups, and found 
a relative risk (RR) of 1.04 (p-value 0.913) in the 6-12 hour administration group and 0.925 
relative risk (p-value 0.845) in the 48-54 hour administration group compared to control, 
while the 20-26 hour administration group had a relative risk of 0.37, with a p-value of 
0.14, indicating a trend. Relative risks evaluations are usually done with group sizes of 50, 
so it was very encouraging to see a statistical trend with our small group size: it suggests a 
strong effect.  
 These results are similar to those reported in the FLAME clinical trial (Chollet et 
al., 2011), where they saw no effect on infarct volume and some hemorrhagic 
transformation in patients given 20 mg fluoxetine beginning two days after stroke and 
continuing for 90 days.  Also, we previously saw that female stroke rats just given 5 mg/kg 
fluoxetine and 20 mg/kg ascorbic acid 20-26 hours after stroke and continued for 30 days, 
had a roughly 11% motor recovery, as assessed by Montoya Staircase. This roughly 
matched the recovery seen in the FLAME clinical trial using the Fugl Meyer Assessment 
score when stroke patients were given only 20 mg fluoxetine daily (A. M. Corbett et al., 
2015). Although our dose was twice that given in the FLAME trial. 









95% CI of diff. Significance 
Control vs. 6-12hrs 8.035 7.626 0.4092 -2.518 to 3.337 No 
Control vs. 20-26hrs 8.035 4.782 3.253 0.1746 to 6.331 Yes  
p=0.0366 













Figure 20. Direct comparison of infarct volumes between all groups treated with 
fluoxetine and ascorbic acid at different time points following stroke induction 
indicates that infarct volume varies with the timing of fluoxetine delivery post-stroke. 
There are no outliers at either end of the range. Each dot represents a single animal 
in each group. The x-axis displays treatment groups at different time points, and the 
y-axis shows the infarct volume in mm3.  The broad horizontal bar indicates the group 
mean and the error bars represent SEM.  *p = 0.0366 using one-way ANOVA with 
Dunnett’s multiple comparisons. 
 
These results are consistent with previous findings in our lab on female rats. The 
methods are similar to previous work with few exceptions: 1) in the previous work we 
examined infarct volumes on day 91 after stroke induction and rats were not on simvastatin 
before the surgery; 2) we added a new time-point (48-54 hours) of drug administration after 




Figure 21. Representative images showing H&E stained coronal brain sections with 
infarcts in male rats. (A). Control (simvastatin only) administered 7 days pre-stroke 
and 7 days post-stroke shows large infarct volume with hemorrhagic transformation. 
(B). Infarct size was unchanged if fluoxetine and ascorbic acid was administered 6-12 
hours after stroke and had a highest relative risk of hemorrhagic transformation.  
(C). Significant reduction of both infarct volume and hemorrhagic transformation 
when fluoxetine and ascorbic acid combination was administered 20-26 hours after 
stroke surgery. (D). The panel shows same infarct size when drug combination was 
delayed 48-54 hours; a possible bleeding (hemorrhagic transformation) is marked 





3.1.2 To improve the sensitivity of the Forelimb Asymmetry test by refining wall touches 
into a more specified parameter that correlates better with functional tests from Montoya 
staircase. 
 
Forelimb Asymmetry analysis is routinely used in small rodents to predict 
functional motor deficits caused by focal ischemic stroke; however, we found that results 
of this test are not as sensitive as the Montoya Staircase test. The aim of this part is to refine 
the forelimb asymmetry analysis to strengthen the sensitivity of the assessment. A 
traditional Forelimb Asymmetry test, which counts all wall contacts, fails to detect 
consistent functional deficits where the Montoya Staircase has identified a functional 
deficit.  Understanding that the hand movements in the two tests are different, with the 
Montoya Staircase using finer motor control for grasping, I nevertheless wanted to 
determine if some of the wall touches in the Forelimb Asymmetry test could be considered 
“abnormal” when compared with pre-stroke functional analysis, and if the sensitivity of 
the test would be increased if abnormal touches were not counted.   In this study in 
particular, I investigated whether counting only palmar pads pressed to the wall rather than 
any attempt to touch the cylinder wall (e.g. by fingertips) would allow a better correlation 
with Montoya staircase results.   This section deals with the functional data from the male 
rat groups shown in Table 7 and also some female rats who were given 5 mg/kg fluoxetine, 
1 mg/kg simvastatin and 20 mg/kg ascorbic acid beginning 20-26 hours post-stroke 























Figure 22.  Rat’s left forelimb shows palmar pads and fingertips. 
 
To evaluate if any touches to the wall were abnormal after the stroke, I needed to 
determine if the normal rat pre-stroke ever touched the wall of the cylinder with only its 
fingertips or if it instead used its palm pressed to the wall (see Figure 23 for different types 
of wall touches).  These data are detailed in Table 9, showing that there were no touches to 
the wall using only fingertips with pre-stroke animals:  this type of touching only occurred 
after the stroke induction.  This type of wall touch could then be considered abnormal, as 





Figure 23. Forelimb Asymmetry analysis. (A). A post-stroke animal rearing and 
placing the palmar pads on the wall, which indicates its use for body support. (B). 
Post-stroke animal leaning on enclosing wall using right (ipsilateral) forepaw while 








Table 9. Number 
of contacts made 
by animal’s left 




the number of wall 
contacts made by 
each animal before 
and after stroke 
surgery indicates 
that attempts to 
touch the wall with 
fingertips only 
occur after stroke 
surgery, which 
strongly indicates 























(Post-Stroke Day 4) 
Palmar Pads Fingertips Palmar Pads Fingertips 
L R L R L R L R 
901 66 61 0 0 10 36 3 3 
902 42 37 0 0 31 103 18 3 
903 58 54 0 0 25 85 7 1 
904 26 26 0 0 1 17 3 1 
905 30 33 0 0 4 19 12 0 
906 70 73 0 0 9 83 29 0 
907 45 42 0 0 20 63 16 0 
909 35 33 0 0 23 34 5 0 
910 50 35 0 0 23 33 0 0 
911 27 30 0 0 118 55 10 0 
912 31 35 0 0 7 30 7 0 
913 32 36 0 0 2 18 10 0 
915 23 25 0 0 24 33 0 0 
916 74 84 0 0 27 40 5 0 
917 54 46 0 0 0 63 17 0 
919 69 72 0 0 18 39 5 0 
921 52 55 0 0 29 36 3 0 
922 59 32 0 0 29 53 20 0 
923 57 61 0 0 10 49 20 0 
925 15 15 0 0 2 6 3 1 
927 34 33 0 0 6 47 16 0 
928 23 25 0 0 0 29 18 0 
929 24 22 0 0 10 23 7 0 
931 23 33 0 0 2 7 3 0 
932 13 13 0 0 0 4 3 0 
935 20 14 0 0 3 15 9 0 
937 8 13 0 0 5 9 1 0 
938 36 37 0 0 0 17 5 0 
939 24 30 0 0 0 30 6 0 
940 39 42 0 0 0 40 14 0 
941 6 6 0 0 3 6 2 0 
943 19 26 0 0 0 17 5 0 
944 26 27 0 0 9 6 0 0 
945 23 25 0 0 3 21 3 0 
946 16 13 0 0 9 7 0 0 
947 23 29 0 0 0 2 0 0 
950 31 32 0 0 0 24 14 0 
951 19 20 0 0 3 13 1 0 
953 13 27 0 0 5 26 2 0 
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Table 10. This contingency table shows animals that made fingertip contacts to the 
wall vs. the ones that did not (before/after stroke surgery), indicated that fingertip 









Fingertip touches 0 34 34 
No fingertip touches 39 5 44 
Total 39 39 78 
p-value < 0.0001 (Fishers exact test ) 
 
To refine wall touches, the numbers of ipsilateral and contralateral contacts made 
by the animal were first quantified before surgery to establish the baseline, then four days 
after stroke surgery to evaluate the functional deficit. We looked at the percentage of 
touches to the wall by right or left paw post-stroke and divided that by their pre-stroke 
performance rates.  When the quotient is 1, the animal had fully regained pre-stroke 
function, and when the quotient is less than 1, the animal had a functional deficit in that 
limb.  In this modified analysis, I focused on the contralateral side performance by counting 
any touch to the wall, whether by the palm or the fingertips and compared the percentage 
of deficit obtained from this quantification method to the percentage of deficit obtained 
when counting touches made by animal palm (fingertip touches are not included). This 
refined approach indicates that counting only the numbers of contacts made by palmar pads 
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is a more sensitive behavioral analysis of functional deficit than including amounts of 
touches made by both palmar pads and fingertips.  
A paired t-test with Welch’s correction for unequal variances was used for 
statistical comparison of the percentage of the contralateral deficit before and after stroke 
using the two methods of counting. Figure 24 (B) showed a reduced functional deficit and 
improved motor recovery when fingertips touches were included in the analysis, which 
gave us reduced sensitivity in the assay.  Counting only the palmar touches, however gave 
us contralateral functional deficits that were consistent with the contralateral functional 
deficits seen in the Montoya Staircase case on Post-stroke days 3, 4, and 5 (Panel A).   
Again, although these tests use different muscles, this seemed to be a good initial indication 
that evaluating the Forelimb Asymmetry response with palmar touches only was an 
improvement.   
     In Table 11, Forelimb Asymmetry % contralateral deficit, calculated with either palmar 
touches (middle column) or palmar and fingertip touches (final column) were compared to 
the contralateral % deficit in Montoya Staircase.  The female rats were included to 
determine if there were any sex differences in the response.  In Figure 25 we separated the 
male rats and in Figure 26 we separated the female rats to perform a linear regression and 








Figure 24. Percentage of the contralateral deficit in Montoya Staircase analysis versus 
Forelimb Asymmetry analysis using two methods of counting the wall touches. (A). 
Quantifying only palm touches in cylinder test shows a similar level of contralateral 
deficit correlating with Montoya staircase results (p = 0.573, paired t-test with 
Welch’s correction for unequal variances). (B). including fingertips touches with 
palm contacts (in the same animal) does not accurately reflect the functional deficit 
that showed by Montoya staircase results (p =0.0001). Each dot represents a single 
animal. The x-axis displays functional tests (Montoya Staircase vs. forelimb 
asymmetry (Palm only, A); or palm and fingertips, B). The y-axis shows the 
percentage of contralateral deficit (%) in each rat measured by different analyses. 
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Table 11. Comparison of percentage of contralateral deficit measured by Montoya 
Staircase versus Forelimb Asymmetry (palmar pads contacts and fingertip attempts 
to hit the cylinder wall). Only animals that showed 20% deficit on the contralateral 





































 (Palm touches %) 
Forelimb Asymmetry 
(Palm and fingertip touches 
%) 
901F 0.20 0.58 0.52 
902F 0.93 0.56 0.41 
903F 0.92 0.56 0.48 
904F 0.58 0.89 0.64 
905F 0.93 0.63 0.04 
906F 0.95 0.80 0.36 
907F 1.00 0.53 0.30 
909F 0.50 0.22 0.12 
910F 1.00 0.22 0.22 
911F 0.75 0.48 0.29 
912F 0.95 0.60 0.32 
913F 0.92 0.79 0.15 
915F 0.83 1.00 0.35 
916F 0.30 0.14 0.05 
917F 1.00 1.00 0.61 
919F 0.59 0.35 0.24 
921F 0.50 0.08 0.03 
922F 1.00 0.45 0.26 
923F 0.82 0.65 0.21 
925M 0.25 0.50 0.17 
927M 0.63 0.78 0.37 
928M 0.40 1.00 0.26 
929M 0.38 0.42 0.19 
931M 0.53 0.46 -0.01 
932M 0.30 1.00 0.14 
935M 0.50 0.72 0.24 
937M 0.00 0.06 -0.05 
938M 1.00 1.00 0.54 
939M 0.25 1.00 0.63 
940M 0.81 1.00 0.46 
941M 0.44 0.33 0.09 
943M 0.71 1.00 0.46 
944M 0.86 -0.22 -0.22 
945M 0.45 0.74 0.54 
946M 0.20 -0.02 -0.02 
947M 0.63 1.00 1.00 
950M 0.86 1.00 0.25 
951M 0.44 0.62 0.52 
953M 0.40 0.50 0.35 
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Figure 25.  Linear regression between Montoya staircase deficit and the Forelimb 
Asymmetry wall touches (palm versus palm + fingertips) in male Sprague-Dawley 
rats. Comparing the overall average deficit measured by the two methods shows a 
similar correlation between results of Montoya staircase and Forelimb Asymmetry 
using the two counting methods of wall contacts. The Y intercept or elevation was 
significantly different between the two lines (p = 0.0008).  In a correlation analysis of 
this data, the R-squared value for male Montoya staircase vs. Forelimb Asymmetry 
palm only is R2= 0.1582 with a p-value of 0.0820, and the R-squared value Montoya 
staircase vs. Forelimb Asymmetry that analyzed using both palm and fingertip 
touches is R2= 0.1021 with a p-value of 0.6279.   
 
touching correlated better with the Montoya Staircase Analysis.  In Female rats, we saw a 
10 fold better correlation between the palmar touches and the Montoya staircase percent 
contralateral deficit.  We did see a better correlation with the palmar touches in the male  
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Figure 26.  Linear regression between Montoya staircase deficit and the Forelimb 
Asymmetry wall touch (palm versus palm + fingertips) deficits in female Sprague-
Dawley rats. The elevations or y-intercepts were found to be significantly different 
(p=0.0011).  Correlation analysis of these data showed a better correlation between 
results of Montoya staircase and Forelimb Asymmetry when only palm touches were 
counted. The R-squared value (R2= 0.1674; p = 0.082) was about 10 fold more than 
R-squared value when Forelimb Asymmetry was analyzed using both palm and 
fingertip touches (R2= 0.01413; p = .6279).   
 
rats as well, and the p-value for the R square correlation (0.0824) was remarkably similar 
to that for the female rat using palm touches ( p-value of 0.082).  In each case, the p-value 
for the R square correlation using the palms and fingertips was much higher (p = 0.6279) 
for males and females (p = 0.167).  Again, since the muscles used for grasping are different 
from the muscles used for pressing your hand against a wall, we did not expect a high 
correlation:  the value we obtained seems reasonable in this case.   
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3.2 Specific Aim II 
To investigate the impact of moderate rehabilitation with the impaired arm on 
functional recovery with and without post-stroke drug treatment. 
 
Adult female Sprague-Dawley rats (10-12 month old) underwent a cerebral 
ischemic stroke induced by endothelin-1 and were then treated daily using a drug 
combination of 5 mg/kg fluoxetine and 1 mg/kg simvastatin or a vehicle control beginning 
6-12 hours after stroke induction and continued for a total of 91 days.  On post-stroke day 
eight, the rats were subjected to voluntary physical rehabilitation every other day for five 
and half weeks (a total of 19 days rehabilitation), except when the animals were on 
restricted diet for Montoya Staircase (fasted overnight, 85% of their ad libitum feed for 2 
days). The animal groups in this study are laid out in Table 12.  We performed Montoya 
Staircase to evaluate functional recovery on post stroke days 3-5, 28-30, 58-60 and 88-90.  
All animals were euthanized on post-stroke day 91. 
 
Table 12. Treatment Groups and Rehabilitation for Female Sprague Dawley rats (10-
12 month)  
 
Group Treatment Rehabilitation Duration of 
Treatment 
Group I  (N= 14) Vehicle Control No 90 days 
Group II  (N=14) Vehicle Control Yes 90 days 
Group III  (N=14) 5 mg/kg fluoxetine + 
1mg/kg simvastatin 
No 90 days 
Group IV  (N=18) 5 mg/kg fluoxetine + 
1mg/kg simvastatin 
Yes 90 days 
 
In pre-stroke training, rats retrieved between 16-18 pellets per forelimb by the end 
of training. In the rehabilitation assigned group, there was a significant difference 
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(p=0.002) in the performance of right and left forepaws. More pellets were retrieved using 
right forepaws (ANOVA; Tukey post-hoc test) as shown in Figure 27.  
Evaluating the post-stroke baseline functional deficit (Figure 28) indicates 
statistically significant functional deficit (p<0.001) in post-stroke contralateral sides of 
both rehabilitation and non-rehabilitation animals (approximately 55% and 66% functional 
deficit, respectively) compared to the ipsilateral side, but no significant difference between 
rehabilitation and non-rehabilitation baseline deficits for contralateral function. The 
ipsilateral side baseline deficit (26%) of the non-rehabilitation group was found to be 
significantly different from the rehabilitation group (3%) (p<0.001). This may have been 
caused by slight differences in the depth of endothelin-1 injection in the stroke induction 
surgeries, causing the infarct to extend into the corpus callosum.  
By examining the influence of physical rehabilitation on contralateral functional 
recovery (Figure 29), we noticed that the percentage of contralateral functional recovery 
(26%) in the control rehabilitation group is enhanced compared to the non-rehabilitation 
group (8.6%), (p =0.014); however, there was no difference in the percentage of 
contralateral functional recovery between the fluoxetine & simvastatin (FS) rehabilitation 
group and the FS non-rehabilitation group, where both are showing 34% contralateral 
recovery (p = 0.98). We did note that the drug plus rehabilitation group reached its 34% 
recovery in 30 days, while the drug only group took the entire 90 days to reach 34% 
recovery, showing a steady increase each month.   Overall, there is a significant difference 
between drug-treated groups and control groups (p =0.037) and a significant difference 
between non-rehabilitation FS group and non-rehabilitation control group (p =0.014) as 
analyzed with two-way ANOVA.  
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Both control and drug non-rehabilitation groups show about 23% of ipsilateral 
functional recovery, which was statistically significant (p<0.05) compared to the ipsilateral 
functional recovery in control and drug rehabilitation groups (~-0.1%) (Figure 30).  Of 
course, the rehabilitation groups did not show an ipsilateral deficit in their baseline deficit 
following stroke surgery (see Figure 28), so it is not surprising there was no recovery.   
Overall, these results suggest that the post-stroke drug combination may allow for 
functional motor recovery in individuals for whom physical rehabilitation may not be 



















Figure 27. Montoya Staircase Pre-stroke Training. The y-axis depicts the number of 
pellets retrieved in each group using contralateral (blue bar) or ipsilateral (red bar) 
forelimb before stroke induction. The x-axis shows the rehabilitation assigned group 
vs. non-rehabilitation. The graph indicates a significant difference (two-way ANOVA, 
p=0.002; Tukey post-hoc test) between ipsilateral and contralateral forepaw 




















Figure 28. Montoya Staircase Post-Stroke Baseline Functional Deficit. The y-axis 
depicts functional deficit in contralateral (blue bar) or ipsilateral (red bar) forelimb. 
The x-axis shows the rehabilitation assigned group vs. non-rehabilitation. The graph 
indicates a significant functional deficit (p<0.001) in post-stroke contralateral sides of 
both rehabilitation and non-rehabilitation groups compared to ipsilateral sides. The 





















Figure 29. Effect of Physical Rehabilitation on Contralateral Functional Recovery. 
Yellow bars denote control groups, and green bars denote FS drug treated groups. 
Rehabilitation groups are indicated by hatched bars, and non-rehabilitation groups 
are indicated by solid bars.  The graph depicts significant difference between drug-
treated groups and control groups (p =0.037), and a significant difference between 
non-rehabilitation FS group (solid green bar) and non-rehabilitation control group ( 






















Figure 30. Effect of Physical Rehabilitation on Ipsilateral Functional Recovery. Both 
control and drug non-rehabilitation groups show about 23% of ipsilateral functional 
recovery, which was statistically significant (p<0.05) compared to the ipsilateral 
functional recovery in control and drug rehabilitation groups. The baseline ipsilateral 
functional deficit in the non-rehabilitation group explains the apparent significant 
recovery when comparing to rehabilitation group that did not show as much 




























3.3 Specific Aim III  
To explore sex-dependent changes in gene expression of inflammation and 
polarization markers expressed by microglia in the peri-infarct zone in response to 
combination drug treatment. Neurotrophic factors and synaptic plasticity genes will also 
be examined in male rats. 
 
The animal groups used in this study are shown in Table 13, with each male group 
having an N of 6 pre-stroke and each female group having an N of 6 pre-stroke.  All animals 
except the control group, were on simvastatin beginning 7 days pre-stroke and continued 
daily throughout the study. The functional tests used are shown in the table and were 
analyzed in the Specific Aim 1.  Animals were euthanized on post-stroke day 7, perfused 
with phosphate-buffered saline, then the brain dissected, blocked and quick frozen in 
isopentene and dry ice.  Peri-infarct region was excised on the cryostat, mRNA prepared,  
 
Table 13.  Male and Female Sprague-Dawley rats: Control group received the vehicle. 
Simvastatin and FSA groups were on 1mg/kg Simvastatin for seven days before 
stroke induction and continued for six days post-stroke, then euthanized. PSD refers 
to Post-Stroke Day. All treatment started at 20-26 hours after stroke.  There was no 
Female Simvastatin only group. 





Male  and Female Control 
Group (N= 6) 
Vehicle PSD 3-5 PSD 4 PSD 7 
Male Simvastatin Group 
(N= 6) 
1 mg/kg Simvastatin PSD 3-5 PSD 4 PSD 7 
Male and Female  
FSA Group  (N= 6) 
5 mg/kg fluoxetine  
 + 1 mg/kg 
simvastatin 
+ 20 mg/kg Vit C 
PSD 3-5 PSD 4 PSD 7 
and reverse transcribed to cDNA with the Qiagen First Strand Kit.  cDNA was then applied 
to custom and purchased micro-array real time PCR microarray plates for analysis of gene 
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expression differences.  All samples in data analysis passed the quality control tests for 
PCR array reproducibility, reverse transcription efficiency, and genomic DNA 
contamination test. Hypoxanthine phosphoribosyl transferase-1 (Hprt1) and lactate 
dehydrogenase A (Ldha) have been chosen from the housekeeping gene panel for 
normalization. Other HK genes such as Ppih, Actb and Nono, were not included since they 
show small variations between the plates. 
Data were analyzed, and statistical significance was assessed by using the online 
software at (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). This online 
tool does statistical analysis by calculating the p-values and fold changes using a Student’s 
t-test (two-tail distribution and equal variances between the two samples) based on the 
Livak method in which, Ct value of the target gene normalized to Ct value of the reference 
gene in each experiment to obtain ∆Ct. Then ∆Ct of the Test Sample normalized to ∆Ct of 
the Control Sample to obtain ∆∆Ct. The Fold Changes in expression is calculated as  2^-
∆∆Ct, and the Fold Regulation is the negative inverse of the fold change. 
 
3.3.1 Results of Profiling Microglia Markers in FSA treated Male Rats vs. Control 
 
RT2 PCR analysis data was presented as fold-change and fold regulations, where 
fold-change 2^(- Delta Delta Ct) is the normalized gene expression 2^(- Delta Ct) in the Test Sample 
divided the normalized gene expression 2^(- Delta Ct) in the Control Sample.  
Fold-Regulation represents fold-change results in a biologically meaningful way. 
Fold-change values greater than 1 indicate a positive or an up-regulation, and the fold-
regulation is equal to the fold-change. Fold-change values less than 1 indicate a negative 
or down-regulation, and the fold-regulation is the negative inverse of the fold-change. The 
93 
 
lists of genes that are presented in result tables were chosen based on fold upregulation >2 
or fold down-regulation <-2. Data was sorted by lowest to highest p-value. The full lists of 
all genes including the ones that did not show a significant change are shown in Apendix 
VII with fold-change and fold-regulation values greater than 2 are indicated in red; fold-
change values less than 0.5 and fold-regulation values less than -2 are indicated in blue. 
 Table 14 represents significantly up-regulated genes in the FSA treatment group 
versus control in male Sprague-Dawely rats. Signal Transducer and Activator of 
Transcription Stat4 and Chemokine (C-C motif) ligand 11 Ccl11 show fold regulation of 
3.74 and 2.08 (p= 0.0323 and 0.0413, respectively). STAT4 protein is involved in both 
classic and alternative immune responses; it binds to specific regions of DNA to promote 
T cell activation and proliferation as well as helps in cytokine production. The molecular 
mechanisms by which STAT4 modulates the immune system are unclear (Wurster, Tanaka, 
& Grusby, 2000). Chemokine (C-C motif) ligand 11 Ccl11 is associated with aging in mice 
and humans (Villeda et al., 2011). Brain-derived neurotrophic factor Bdnf was highly  
Table 14. Genes up-regulated in FSA treated male rats vs. control group with a fold 
regulation >2.  Ccl11 and Stat4 are associated with M1 type microglia, and Bdnf is 











Ccl11  Chemokine (C-C 
motif) ligand 11 
M1 marker 0.0323 
 
3.74 3.74 
Stat4  Signal transducer 
and activator of 
transcription 4 
M1 marker 0.0413 2.08 2.08 
Bdnf  Brain-derived 
neurotrophic factor 
M2a and M2c 
marker / 
growth factor 
0.089 3.85   
 




upregulated in male FSA treated animals (fold regulation 3.85) with a trend toward 
significance (p =0.089) compared to control group. BDNF has been found to regulate 
neuronal activity and enhance neurogenesis (Zigova, Pencea, Wiegand, & Luskin, 1998) 
and we believe this growth factor is contributing to both our functional recovery and 
smaller infarct size. Our findings on the down-regulated genes in FSA-treated male rats 
and the corresponding fold regulation and p-values are summarized below in Table 15. The 
only gene that was down-regulated and shows trend towards significance (p=0.094) is the 
inducible nitric oxide synthase 2 (Nos2). This gene is associated with inflammatory M1 
microglia and is believed to cause most of the damage following stroke. 
 




Description Role of 










0.094 0.50 -2.0 
 
 
We used the protein-protein interaction (PPI) information reported in STRING 
software (version 10.0) to predict interactions between genes in certain pathways. We first 
examined the interaction of the highly up-/down-regulated genes with tightly stringent 
approach, followed by a loose stringent approach. The networks were identified from a list 
of pathways based on the count of gene involved and a False Discovery Rate (FDR) 




3.3.2 Analysis of Protein-Protein Interaction (PPI) in Microglia Markers: 
Upregulated Microglia Genes in FSA-treated Male Rats vs. Control 
 
PPI Analysis: Network does not have significantly more interactions than expected. This 
means that current set of proteins is either rather small (i.e. less than 5 proteins or so) or 
that it is essentially a random collection of proteins that are not very well connected (see 






Figure 31. Predicted protein-protein interaction network (PPI) of the up-regulated 
genes in male FSA treatment group created by STRING 10.0 (tight stringency) 
(Threshold: 0.4, medium confidence).  
 
of proteins, it could simply be that these proteins have not been studied very much and that 
their interactions might not yet be known to STRING. All genes that belong to same 
pathway are represented in red highlighted nodes.  
Both Ccl11 and Stat4 are M1 microglia biomarkers that are involved in chronic 
inflammatory response. Bdnf gene, however, is an M2 biomarker and essential contributor 
in neurogenesis. The large nodes suggest that some 3D structure is known or predicted. 












Figure 32. Predicted protein-protein interaction network (PPI) of up-regulated genes 
in male FSA treatment group (loose stringency) shows 5 genes involved in 
inflammatory response and positive regulation of cell communication. (Threshold: 
0.4, medium confidence).  
 
In Figure 32, we examined protein-protein interaction of the upregulated genes in Male 
FSA versus control with loose stringency.  Here we see growth factors or their receptors 
up-regulated (Bdnf, Fgf9 and Npy2r) with upregulation of Stat3, a M2 microglial marker.  
The network shows interaction between Stat4, Ccl11 (M1 markers) and Stat3 (M2 marker) 
because these shifts are fluid rather than absolute, retaining some markers as the shift 
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occurs.  We begin to see interactions between the neuropeptide Y receptor 2 and Gal 
receptor1, and also see some signs of stress (upregulated corticotropin-releasing hormone 
releasing hormone and its binding protein), but the binding protein may actually be 
reducing the stress effect by preventing Crh binding to its receptor. 
 
 
Figure 33. Predicted protein-protein interaction network (PPI) of down-regulated 
genes in male FSA treatment group (loose stringency) shows a large count of genes 





     In Figure 33, we see a general downregulation of inflammatory factors (Cd40, Il6, Stat1, 
Nos2, Tnf) but we also see some beginning downregulation of some anti-inflammatory 
factors (Tgfb, Il10ra, Arg1(M2 microglia marker)).  We see downregulation of Crh 
receptors and downregulation of some growth factors and neuroplasticity markers.   
 
3.3.3 Results of Profiling Microglia Markers in FSA treated Female vs. Control 
 
Table 16. Up-regulated genes with fold regulation >2 in female rats treated with FSA 










Sox2  SRY (sex determining 
region Y)-box 2 
transcription 
factor 
0.047 2.5115 2.5115 
Crhr1 Corticotropin releasing 
hormone receptor 1 
receptor in 
rat microglia 
0.103 2.4755 2.4755 
Camk2g Calcium/calmodulin-




0.125 2.1039 2.1039 






0.147 2.3538 2.3538 
Crhbp Corticotropin releasing 
hormone binding protein 
Neuropeptide 0.215 2.2195 2.2195 
Cbln1 Cerebellin 1 precursor Neuronal 
apoptosis 
0.310 2.0208 2.0208 
Nell1 NEL-like 1 Apoptotic 
factor 
0.412 2.1142 2.1142 
 
Table 16 show a significant upregulation of Sox2 in female rats, which is a 
transcription factor important for maintaining self-renewal of undifferentiated embryonic 
stem cells. Sox2 plays a vital role in maintenance of neural stem cells. Other upregulated 
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genes that show trend toward significance are Crhr1, Camk2g, Crh, Crhbp, Cbln1 and 
Nell1.  
Crhr1 gene encodes corticotropin releasing hormone receptor-1 (CRH-R1). Both 
in vitro studies on embryonic rat microglia culture (W. Wang, Ji, Riopelle, & Dow, 2002), 
and in vivo studies (Stevens et al., 2003) found that CRH-R1 and CRH-R2 receptors are 
expressed on microglia in rodent’s brain with CRH-R1 being the predominant receptor 
expressed in rat brain microglia. These findings suggest that microglia may play a role in 
mediating effects of corticotropin releasing hormone in brain under normal and 
pathological conditions.  
Table 17 indicates a reasonable trend of down-regulation of Arginase Arg1, which 
is an M2a and M2c biomarker that involved in cellular response to hydrogen peroxide, 
tissue remodeling, response to toxic substance and response to wounding (Kolluru, Bir, & 
Kevil, 2012).  
 
Table 17. Down-regulated genes in female rats treated with FSA 
Down-regulated 
Genes 






Arg1 Arginase M2a, M2c 
marker 
0.155 0.3795 -2.6353 
 
3.3.4 Analysis of Protein-Protein Interaction (PPI) in Microglia Markers:      
Up-regulated Microglia Genes in FSA-treated Female Rats vs. Control 
 
PPI Analysis:  The network has significantly more interactions than expected. Proteins 
have more interactions among themselves than what would be expected for a random set 
of proteins of similar size, drawn from the genome. Such an enrichment indicates that the 
proteins are at least partially biologically connected, as a group. 
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For tight clustering using only the upregulated genes from Table 16, the predicted 
graph shows the highest number of genes are involved in two networks consisting of 6 and 
4 genes. These networks are: single-organism cellular process and regulation of synapse 











Figure 34. PPI analysis of up-regulated genes in female FSA treatment group (tight 
stringency). (A). Genes involved in single-organism cellular process. (B). Genes play 











Figure 35. PPI analysis of up-regulated genes in female FSA treatment group (loose 





     In Figure 35, we see interactions that may have occurred if we had used a higher N in 
our gene analysis to obtain lower p values.   We see a stress network (Crh receptors and 
binding protein) connected to synaptic plasticity network (Creb1, Camk2a, Camk2g, Bdnf) 
and also see more growth factors upregulated.  This network is strikingly more complex 
than that seen in male rats with the same drug treatment. 
 
3.3.5 Results of Profiling Microglia Markers in Simvastatin-treated Male Rats vs. 
Control 
Testing samples from male rats pre-treated with simvastatin for 7 days before stroke 
surgery, and 6 days after stroke induction shows that Chemokine (C-C motif) ligand 11 
(Ccl11), which is associated with M1 microglia, is significantly up-regulated as seen in 
FSA treated male rats but not FSA treated females. In addition, both cerebellin 1 precursor 
and Brain-derived neurotrophic factor were highly expressed. 
 











Ccl11 Chemokine (C-C 
motif) ligand 11 
M1 marker 0.022319 2.3405 2.3405 
Cbln1 Cerebellin 1 precursor Regulates 
synapse 
function 












In contrast to FSA treated males, none of the genes in simvastatin treatment group 
was significantly down-regulated to -2. This suggests a possible essential role of fluoxetine 
as an anti-inflammatory agent inhibiting the inducible nitric oxide synthase 2 (Nos2), which 
associated with inflammatory M1 microglia. 
3.3.6 Analysis of Protein-Protein Interaction (PPI) in Microglia Markers:      
Up-regulated Microglia Genes in Simvastatin-treated Male Rats vs. Control 
 
PPI Analysis: As seen in FSA male groups, network does not have significantly more 
interactions than expected. Although the upregulated genes are not directly connected to 
each other, the STRING system proposed that all of these genes are involved in positive 
regulation of cellular component biogenesis and both Bdnf and Cbln1 contribute to positive 
regulation of synapse assembly.  
 
Figure 36. PPI analysis of up-regulated genes in male simvastatin treatment group. 
(Tight stringency) (Threshold: 0.4, medium confidence).  
 
 Figure 36 shows the protein-protein interaction analysis with loose stringency to 
both upregulated and down-regulated genes displays 16 up-regulated genes that are 
connected in positive regulation of signal transduction. We see upregulation of growth 
factors and their receptors (Bdnf, Cntf, receptors for neuropeptide Y) and synaptic plasticity 
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genes.  Interestingly, we see association of the Stat genes that are associated with the 
different M1 and M2 microglial subtypes, as well as other associated markers, again 
suggesting a fluid transition from one microglial subtype to another. These genes seem to 
be predominately anti-inflammatory.  On the other hand, three of the down-regulated genes 
(Vegfa, Nos2 and il6) appear to be involved in hypoxia-inducible factor (HIF-1) signaling 
pathway that mediates the cellular oxygen signaling pathway, and plays a multifaceted role 
of HIF-1 in outcomes of ischemic stroke  (Kalakech et al., 2013), (Sharp, Bergeron, & 













Figure 37. PPI analysis of up-regulated genes in male simvastatin treatment group 






3.3.7 Comparing the Expression of Microglia Markers in FSA treated Female Rats to 
FSA treated Males 
 
Examining changes in gene expression patterns in female rats in relation to same 
age male rats that received same drug combination treatment (used as control in this 
analysis) showed a tendency towards statistical significance in the expression of a potent 
neurotrophic factor, GDNF family receptor alpha 3 (Gfra3), with a 6 fold increase. This 
protein play key role in the control of neuron survival and differentiation. Other up-
regulated genes in response to the FSA treatment in female rats are: cluster of 
differentiation (Cd163 gene), which is an M2 microglia marker that is expressed when 
microglia is recruited to sites of ischemia (Cherry, Olschowka, & O'Banion, 2014). CD163 
protein functions in hemoglobin scavenging (Kowal et al., 2011), and it has been used in 
experimental studies to identify M2 microglia in rat traumatic brain injury (Z. Zhang, 
Zhang, Wu, & Schluesener, 2012). Moreover, multiple pro-inflammatory biomarkers of 
M1 microglia appear to be up-regulated in females compared than male rats, which include 
Il1b, Nos2, Tnf, Stat1, il10ra and Il6 cytokines.  
Although there was no significant difference in gene expression between the two 
tested genders, this pattern of response to the drug treatment in female rats may promote 
future studies to build on these findings and determine whether the two genders are 
significantly different from one another. Significant variation could be seen after increasing 
the number of experimental animals. 
Gene regulation pattern in female FSA treated animals vs. male FSA treated animal 











Description Role of the 
gene 




Gfra3 GDNF family 
receptor alpha 3 
Neurogenesis 0.084574 5.8624 5.8624 
Cd163 CD163 molecule Cytokine 0.089223 3.0674 3.0674 





0.105728 2.2289 2.2289 
Il1b Interleukin 1 beta Cytokine 0.150449 3.2735 3.2735 
Nos2 Nitric oxide synthase 
2, inducible 
M1 marker 0.174178 2.371 2.371 
Tnf Tumor necrosis 
factor 
Cytokine / M1 
marker 
0.273191 3.012 3.012 
Tgfb1 Transforming growth 
factor, beta 1 
Growth factor 0.295521 2.6995 2.6995 
Cxcr4 Chemokine (C-X-C 
motif) receptor 4 
Cytokine / M1 
marker 
0.346437 3.4937 3.4937 
Stat1 Signal transducer and 
activator of 
transcription 1 
M1 marker 0.352873 2.3304 2.3304 
il10ra Interleukin 10 
receptor, alpha 
Cytokine / M1 
marker 
0.464164 2.0297 2.0297 





0.487533 2.4509 2.4509 
Gmfg Glia maturation 
factor, gamma 
Growth factor 0.582022 2.2929 2.2929 








3.3.8 Analysis of Protein-Protein Interaction (PPI) in Microglia Markers:      
Up-regulated Microglia Genes in Female FSA vs. Male FSA Group 
 
  
PPI Analysis:  Network has significantly more interactions than expected. Figure 38 shows 
six genes in the tight stringency analysis appear to influence positive regulation of response 
to external stimulus. These are the neurotrophic factor ciliary neurotrophic factor (Cntf), 
M1 microglia markers; interleukin 1 beta (Ilb), Tumor necrosis factor (Tnf), Interleukin 6 
(Il6) and Chemokine (C-X-C motif) receptor 4 (Cxcr4) (red highlighted nodes in Figure 
38). In the loose stringency prediction, half of all upregulated genes are involved in signal 
transduction and cell communication (Figure 39). 
 
Figure 38. PPI analysis of up-regulated genes in female FSA treatment group 












Figure 39. PPI analysis of up-regulated genes in female FSA treatment group 
compared to male FSA group (loose stringency). Graph indicates that (Threshold: 




3.3.9 Comparing the Expression of Microglia Markers in Female Control against 
Male Control Group 
Profiling gene expression in female control group against male control (Table 20) 
shows that Sox2 is the only significant down-regulated gene with a p-value 0.046. A group 
of 10 other genes were down-regulated with at least a -2 fold regulation. This may indicate 
a sex-dependent difference in gene expression pattern in response to endothelin induced 
stroke. The down-regulated genes are presented in the table below and their predicted 
interactions are demonstrated in Figures 40 and 41.  











Sox2 SRY (sex determining 
region Y)-box 2 
Transcription 
factor 
0.046 0.403 -2.4814 
Cntfr Ciliary neurotrophic factor Neurotrophic 
factor/ Cell 
differentiation 
0.074 0.4995 -2.0022 
Camk2g Calcium/calmodulin-




0.130 0.4639 -2.1558 
Fgf9 Fibroblast growth factor 9 Cell 
differentiation 
0.1307 0.4431 -2.2566 
Npy2r Neuropeptide Y receptor 
Y2 
Neuropeptide 0.151 0.4974 -2.0105 
Crhr1 Corticotropin releasing 
hormone receptor 1 
CRH receptor 0.172 0.4365 -2.2911 
Npy1r Neuropeptide Y receptor 
Y1 
Neuropeptide 0.268 0.4962 -2.0152 
Cbln1 Cerebellin 1 precursor  0.286 0.4205 -2.3784 
Arg1 Arginase M2 marker 0.343 2.6161 2.6161 
Camk2a Calcium/calmodulin-




0.415 0.4426 -2.2593 
Nell1 NEL-like 1 Apoptotic 
factor 
0.443 0.4082 -2.4496 
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3.3.10 Analysis of Protein-Protein Interaction (PPI) in Microglia Markers:      
Down-regulated Microglia Genes in Female Control vs. Male Control Group 
 
PPI Analysis:  The network has significantly more interactions than expected. In Figure 
40, regulation of synapse structure or activity is the only predicted biological pathway in 
which 4 genes are involved. These genes are (Crhr1, Camk2a, Camk2g and Cbln1). Under-
expression of these important genes in control untreated female rats when compared to 
control males worth further investigation. The loose stringency analysis in Figure 41 shows 
that genes are primarily involved in signal transduction and cellular response to 




Figure 40. PPI analysis of down-regulated genes in female control group compared 















Figure 41. PPI analysis of down-regulated genes in female control group compared 






3.3.11 Results for Neurotrophic Gene Profiling in Male Rats 
  
Gene analysis of neurotrophic factors and their receptors shows upregulation of 
multiple growth factors and their receptors in Table 22 and downregulation of genes in 
Table 23. Male (10-12 months) Sprague-Dawley rats that were treated with FSA for 7 days 
after stroke and were compared to vehicle control in this gene expression analysis 
according to the groups are listed in Table 22. 
 
Table 21. Treatment groups for genetic analysis of neurotrophic factors 
 
RT-qPCR Array Control Group FSA Group 
Neurotrophins and Receptors N=6 N=5 
 
In Table 23, one of the markedly up-regulated genes is orexin (also known as 
hypocretin HcRt) with a trend towards significance in FSA treated group of male Sprague-
Dawley rats. This was similar to previous results in female rats using this same microarray 
plate. In the current study on male FSA treated vs. control, orexin (HcRt) shows about 10 
fold of increase (9.92). Our previous work on female rats (10-12 month) treated with the 
same dose of FSA for 10 days after stroke showed that HcRt was upregulated to 2.06 fold. 
Another experiment in our lab on female 10-12 month rats using fluoxetine and simvastatin 
(FS) without ascorbic acid for 10 days treatment indicates that orexin receptors Hctr1 and 
Hctr2 are up-regulated to 2.07 and 2.93, respectively ( p <0.05).  This suggests that males 
and females may require different drug combinations for optimal recovery after stroke. 
A summary of the main orexinergic pathways and receptor mRNA distribution in 
the rat brain is illustrated in Figure 42. Note particularly that the orexin receptors are in the 
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cortex itself, and are thought to increase Bdnf when activated.  In human stroke patients, 
decrease in orexin in the blood following stroke has been observed.  This upregulation of 
receptors that we see may help counter the drop of orexin in this region, helping more of 
the cortex survive.  Other potential players in the possible neuroprotective role of the drug 
combination are listed below in Table 22 and Table 23.  
 
Table 22. Neurotrophic Factors and Receptors: Gene profiling in male Sprague-











Nr1i2 Nuclear receptor 
subfamily 1, group 
I, member 2 
Transcription 
factor 
0.039 3.77 3.77 
HcRt Orexin/Hypocretin Neuropeptide 0.128 9.92 9.92 
Grpr Gastrin releasing 
peptide receptor 
Neuropeptide 0.132 2.24 2.24 
Bdnf Brain-derived 
neurotrophic factor 
M2a and M2c 
marker/ 
growth factor 




Table 23. Neurotrophic Factors and Receptors: Gene profiling in male Sprague-















0.031 0.40 -2.47 
Il1b Interleukin 1 beta M1 
marker 
0.032 0.38 -2.57 
Il10 Interleukin 10 M1 
marker 
0.059 0.45 -2.21 
Lif Leukemia inhibitory 
factor 
Cytokine 0.149 0.28 -3.52 
Hspb1 Heat shock protein 1 Apoptotic 
factor 
0.160 0.35 -2.79 
Il6 Interleukin 6 M1 
marker 
0.210 0.36 -2.74 
Cxcr4 Chemokine (C-X-C 
motif) receptor 4 















Figure 42. The schematic diagram illustrates the majority of orexinergic pathways 
and locations in brain. The level of expression varies between areas. CA1–3 = areas 
of hippocampus; CC = cingulate cortex; CMN = centromedial nucleus; DRN = dorsal 
raphe; LC = locus coeruleus; MRN = median raphe nucleus; NST = nucleus of solitary 
tract; olfB = olfactory bulb; olfT = olfactory tubercle; PVN = paraventricular 
nucleus; NRM = nucleus raphe magnus; RO = nucleus raphe obscurus; SCN = 
suprachiasmatic nucleus; SON = supraoptic nucleus; STN = spinal trigeminal 
nucleus; TMN = tuberomamillary nucleus; VAMN = ventral anteromedial nuclei. 
Adapted from The Hypothalamic Orexinergic System: Pain and Primary Headaches 





3.3.12 Analysis of Protein-Protein Interaction (PPI) within Neurotrophic Genes in 
Male Rats 
 
PPI Analysis: The tight stringency analysis of upregulated genes for Male FSA versus 
control is shown in Figure 43.  The network does not have significantly more interactions 
than expected. This could be explained by the small number of interacting proteins or 
because it is essentially a random collection of proteins that are not very well connected. 
Again, this does not necessarily mean that it is not a biologically meaningful selection of 
proteins, it could be that these proteins have not been studied very much and that their 
interactions might not yet be known to STRING.   
    The loose stringency analysis of the upregulated genes in Figure 45 indicates that the 











Figure 43. PPI analysis of up-regulated neurotrophic genes in male FSA group 






On the other hand, PPI prediction shows that down-regulated neurotrophic factors 
are part of regulatory pathway of programmed cell death (Figure 44, A) and inflammatory 

































Figure 44. PPI analysis of down-regulated neurotrophic genes in male FSA group 
compared to male control group (tight stringency). A. Genes that involved in 


















Figure 45. PPI analysis of up-regulated neurotrophic genes in male FSA group 
















Figure 46. PPI analysis of down-regulated neurotrophic genes in male FSA group 




3.3.13 Results for Synaptic Plasticity Gene Profiling in Male Rats 
 
Table 24 shows the number of animals used in RT-qPCR analysis of synaptic 
plasticity gene upregulation in male (10-12 months) Sprague-Dawley rats that treated with 
FSA for 7 days after stroke were compared to vehicle control. 
 
Table 24. Treatment groups for genetic analysis of synaptic plasticity factors 
  
RT-qPCR Array Control Group FSA Group 
Synaptic Plasticity N=6 N=5 
 
 
 Profiling of synaptic plasticity genes of FSA-treated male animals in Table 25 
(upregulated genes) shows increase in a cell adhesion gene, Protocadherin 8 (Pcdh8) that 
may be confirmed by increasing number of animals. The results of profiling synaptic 
plasticity genes were uploaded to STRING program and investigated for any protein-
protein interactions under loose and stringent clustering settings. 
 
Table 25. Synaptic Plasticity Gene Profiling in Male Sprague-Dawley rats: Table 










Pcdh8 Protocadherin 8 Cell 
adhesion 
0.218854 2.851 2.851 
 
 
Table 25 shows the downregulated genes in Male FSA treated group versus control when 
using the Synaptic Plasticity RT PCR microarray plate.  Interestingly, we see 
downregulation of matrix metallopeptidase 9, which is thought to be involved is 
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hemorrhagic transformation after stroke.  The FSA treated rats had a lower relative risk of 
hemorrhagic transfomation compared to controls. 
 
Table 26. Synaptic Plasticity Gene Profiling in Male Sprague-Dawley rats: Table 















0.177072 0.4552 -2.1968 
Cebpd CCAAT/enhancer binding 





0.186163 0.3841 -2.6035 
Igf1 Insulin-like growth factor 1 Long Term 
Depression 
(LTD) 





















3.3.14 Analysis of Protein-Protein Interaction (PPI) within Synaptic Plasticity Genes 
in Male Rats 
 
PPI Analysis:   In Figure 47, the network does not have significantly more interactions 
than expected due to the number of tested genes or the lack of information about their 
interactions. The PPI prediction suggests that two of the down-regulated genes, Igf1 and 
Mmp9, are involved in transcriptional misregulation in cancer, but Mmp9 is also associated 
with damage in stroke. As shown in a previous study on adult male mice (J. Y. Lee et al., 
2012), fluoxetine in the drug combination appears to down-regulate matrix metalloprotease 
gene (Mmp9) which responsible for degrading the extracellular matrix proteins and 















Figure 47. PPI analysis of down-regulated synaptic plasticity genes in male FSA 
group compared to male control group (tight stringency). 
 
 
The backbone network in Figure 48 (loose stringency of upregulated genes) 
consists of 29 nodes of which 20 genes (red nodes) are involved in positive regulation of 
cellular process with medium to high interactions. Upregulating of these genes reveals a 
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positive role of the FSA drug combination in synaptic plasticity in male rats as seen before 
in females. These genes in a different network pattern are involved in learning, 
neurogenesis, protein binding, and regulation of apoptotic process, cell communication, 




Figure 48. PPI analysis of up-regulated synaptic plasticity genes in male FSA group 
compared to male control group (loose stringency). The 3D structure of the majority 




One interesting gene family network in the down-regulated genes (although they 
are not significant), is their clustering in glutamatergic synapse pathway representing the 
metabotropic glutamate receptors. This includes Grm1, Grm2, Grm3, Grm5, and Grm8.  
Glutamate is a key excitatory neurotransmitter that thought to mediate neuronal damage 
after cerebral ischemia by acting upon these receptors  (J. M. Lee, Grabb, Zipfel, & Choi, 
2000).   
 
 
Figure 49. PPI analysis of down-regulated synaptic plasticity genes in male FSA 











Stroke is a cerebrovascular accident that occurs when the normal blood supply to 
the brain is interrupted. With the limited availability of pharmacologic therapy to treat 
stroke and the increase in number of people having stroke along with the cost of treatment 
that is projected to more than double by 2030, there remains a pressing need for finding an 
appropriate post-stroke drug  or drug combination that can prevent long-term disability and 
save lives. 
Preclinical stroke research 
Despite the remarkable investments in advancing translational research; numerous 
pre-clinical stroke studies failed in translating their outcomes into human clinical trials. 
Some reasons that explain this failure are related to poor experimental design in which 
inappropriate animal models employed did not sufficiently simulate the clinical condition 
in humans. The lack of efficient methodologies and accurate data analysis, blinding and 
randomization of experimental data are essential factors that contribute to this unsuccessful 
translation. Also, publication bias and funding resources could hugely influence the 
reliability of studies. We considered a combination of innovative approaches to closely 
mirror what happens in the clinic and bridge the gap between the two sides of translational 
research.  By optimizing the pre-clinical studies design, we aimed at developing the most 
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appropriate animal model and methodologies to increase the translational capability of the 
stroke model.  
Pre-clinical studies in other laboratories have looked at fluoxetine administration 
in animals after stroke induction, or traumatic brain injury, and many have failed to see any 
positive effect of the fluoxetine (Couillard-Despres et al., 2009; Y. Wang et al., 2011; 
Windle & Corbett, 2005). In several of these studies, neurogenesis is examined primarily 
in the dentate gyrus, with only cursory examination of neurogenesis in lateral ventricles 
that are very posterior in the brain (to the side of the hippocampus).  Also, the delivery 
method for fluoxetine is one which would induce stress in the animal (surgical implantation 
of an osmotic pump delivering fluoxetine, daily intraperitoneal injections of fluoxetine, 
oral gavage of fluoxetine, etc.).  We have seen increases in neurogenesis in older (10-12 
month) rats in the subventricular zone (SVZ) of the anterior lateral ventricles in the 
presence of fluoxetine when it is given with voluntary oral administration, thus eliminating 
any stress with the administration of the drug. We also see functional recovery, which 
correlates well with what is being observed in clinical trials of the drug in stroke patients 
(Chollet et al., 2011; Gaillard & Mir, 2011) or traumatic brain injury patients (Horsfield et 
al., 2002). Since stress has an inhibitory effect on neurogenesis and fluoxetine can induce 
neurogenesis (Dwivedi, Rizavi, & Pandey, 2006; Hitoshi et al., 2007), we believe that care 
must be taken to eliminate stress when administering the fluoxetine to animal models of 
disease, which our drug delivery system accomplishes (A. Corbett et al., 2012). 
Animal models are designed to provide therapeutic relevance to human research, 
however, there is an ongoing disconnect between animal studies and human clinical trials 
that can be mainly attributed to either employing improper animal age or sex preference. 
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Gender bias exists in animal stroke models, in which male models are usually employed in 
pre-clinical studies (Dietz, 2006). Consistency with using methods that have been shown 
to induce deficits in an animal model similar to human stroke patients and using a reliable 
method of drug delivery and suitable functional evaluation techniques are fundamental 
factors of sound pre-clinical research. In addition, randomization and blinding of the 
experimenter to treatment conditions are crucial to eliminate bias. 
Since the majority of pre-clinical stroke studies conducted on young rats, they often 
show spontaneous recovery after focal ischemia. To better correlate with the human stroke 
population, animal models need to be middle-aged or older. We use adult male and female 
Sprague-Dawley rats at 10-12 months of age as an animal model of stroke because of their 
age correlates with middle age human, and their blood vessel collateralization is similar to 
the human population. We are assessing differences between females and males, as 
diversity in the response to stroke is clinically relevant. Moreover, we suggest further 
experimentation in a variety of species such as rabbits and guinea pigs and even larger 
animal models to confirm any findings.  
Appropriate Timing of Drug Administration 
Fluoxetine, simvastatin and ascorbic acid combination that was developed in our 
lab might be a potential therapeutic intervention to complement the limited availability of 
thrombolytic therapy rt-PA, and improve functional motor recovery after ischemic stroke. 
Given the results of a previous study in our lab on adult (10-12 month) female Sprague-
Dawley rats (Balch et al., 2015), it appears that delivering fluoxetine 20-26 hours after 
stroke induction not only promotes functional motor recovery but also reduces the infarct 
volume significantly compared to giving the fluoxetine within 6-12 hours of stroke 
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induction. Moreover, administrating the fluoxetine early (6-12hrs) led to developing a 
secondary hemorrhagic stroke in female rats.  
The current work has emphasized the importance of timing in the delivery of the 
fluoxetine to a male rat model of ischemic stroke already on simvastatin.  Studying the 
effect of fluoxetine in an animal model of stroke where the rats were already on statins, 
7days before stroke induction, correlates better with what is seen during clinical trials with 
fluoxetine, as almost a third of the clinical trial patient are on statins. The finding of this 
study in adult (10-12 month) male Sparague-Dawley rats suggests that functional outcome 
might be substantially enhanced by administering fluoxetine within 20-26 hours of a stroke 
rather than having the first delivery at 48-54 hours after stroke. Findings of this study are 
similar to those of females and showed signs of hemorrhagic transformation at both the 
early time point of drug administratinon (6-12 hrs), and delayed time (48-54 hrs) following 
stroke. However, any hemorrhagic transformation in male rats were in the reperfusion 
injury region, extending from the original site of injection and no isolated hemorrhagic 
infarcts were seen in the males, in direct contrast to the females.  
Refining the Functional Assessment of Stroke 
Finding appropriate tests to assess functional outcome in preclinical studies of 
stroke is imperative. Due to the range of different deficits that accompany stroke, a variety 
of functional tests that are sensitive to the extent of damage, location of the stroke, and 
beneficial treatment should be applied. Although there are multiple functional tests, I only 
covered the most commonly performed functional assessments of motor function in the 
rodent stroke model (Montoya staircase and forelimb asymmetry test). Montoya staircase 
is considered more sensitive and able to detect even moderate functional impairments 
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following stroke, due to the fine motor control involved in grasping and holding onto a 
small object. The forelimb asymmetry analysis has the advantages over Montoya’s test in 
that no pre-training of the animals is required, and no expensive apparatus is needed. 
However, a more accurate approach is required to adequately assess functional deficit and 
recovery using this cylinder test.  Behavioral studies traditionally count every touch made 
by the animal to the wall.  I analyzed pre-stroke versus post-stroke wall touches and found 
that fingertip touches to the wall were only seen post-stroke, so are likely to be abnormal 
touching seen only after injury.   In my approach, I calculated the percentage of deficit 
obtained from counting palm touches versus palm and fingertip touches and compared the 
outcome to the results obtained from Montoya staircase analysis. The results showed that 
in female rats there was a slightly better correlation between the results of Montoya 
staircase and the forelimb asymmetry analyses when only palm touches were counted. 
These findings might provide evidence of an increased  sensitivity  of the Forelimb 
Asymmetry test through the use of the modified counting method (palm only counted as a 
normal touch), which needs further confirmation with a larger number of experimental 
animals. By evaluating the available functional assessments in clinical trials, the outcomes 
of both Forelimb Asymmetry test and Montoya Staircase can be translated over to human 
clinical trial studies, with similarities in both the Fugl-Meyer Assessment and the Modified 
Rankin Score. 
Infarct Volumes in Female Sprague-Dawley Rats 
The previous work in our lab to evaluate infarct volume in 10-12 month female 
Sprague-Dawley rats were conducted by using a Cresyl Violet (Nissl) stain, in which slides 
of coronal sections of the brain were stained, cleared and dehydrated using a series of timed 
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washes. After the stained tissue was dry, cover slips were placed over the tissue using a 
permanent mordant DPX (Balch, 2014).  
 Table 27. Female treatment groups with different times of drug delivery. Combined 
medications (5 mg/kg fluoxetine and 1 mg/kg simvastatin) were orally administered either 
beginning 6-12 hours or 20-26 hours after stroke induction and continued daily for 90 days.  
Infarct volumes were assessed at post-stroke day 91 using Nissl stained coronal brain 
sections (representative sections shown in Figure 50).   
 
 In Figure 50, I put together the montages for the Nissl stained brain sections 
(representative figures) used in this publication in which I was a co-first author (Balch et 
al., 2015). This work showed some similar changes to that seen in my work on the male 
rats.  In particular, notice that in panel A and C, which are control animals for 6-12 hour 
and 20-26 hour administration respectively, you can clearly see the injection site for the 
endothelin at the top of the cortex, and to the right of this site there is extensive damage 
which is likely caused by reperfusion injury.  Inflammatory microglia are thought to be 





6-12 hrs.  Control 
(N=8) 
None PSD 3-5 PSD 4 PSD 91 
6-12 hrs. FS 
(N=11) 
1 mg/kg statin 
5 mg/kg fluoxetine 
PSD 3-5 PSD 4 PSD 91 
20-26 hrs. Control 
(N=8) 
None PSD 3-5 PSD 4 PSD 91 
20-26 hrs. FS 
(N=6) 
1 mg/kg statin 
5 mg/kg fluoxetine 
PSD 3-5 PSD 4 PSD 91 
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involved in both making the blood brain barrier permeable after stroke and allowing 
infiltration of peripheral macrophages and lymphocytes, which cause most of the damage 
in reperfusion injury.  Note that in Panels B and D, where drug treatment with fluoxetine 
and simvastatin has occurred, we do not see the extensive reperfusion damage associated 
with the injection site, although the 6-12 hour drug administration rats do have evidence of 
secondary bleeding.  
Figure 50:  Representative Nissl stained coronal sections showing infarcts from female 
stroke rats (control versus fluoxetine, simvastatin treated) at two different administration 
time-points.  These rats received fluoxetine (5 mg/kg) and simvastatin (1 mg/kg) at either 
6-12 hours after stroke (Panel B) or 20-26 hours after stroke (Panel D).  Control rats are in 
panels A and C for 6-12 hours after stroke and 20-26 hours after stroke respectively. The 
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lower infarct on Panel B, with fluoxetine and simvastatin given after 6-12 hours, represents 
a secondary hemorrhagic infarct, totally dissociated from the original infarct site: these 
were only seen in female rats, although male rats did show hemorrhagic transformation 
within the reperfusion injury. Rats were euthanized 90 days post-stroke.  The scale bar 
indicates 500 micrometers. 
Figure 51. Infarct volumes vary with timing of fluoxetine and simvastatin delivery after 
ischemic stroke.  (A). in delayed drug delivery time (20-26 hrs. post-stroke), a strong trend 
of volume reduction was seen using t-test with Welch’s correction for the drug group, 
but missed a significant difference (3 ± 0.3447 mm3 SEM, p =0.0563). (B). Infarct volumes 
in early drug delivery time (6-12 hrs. post-stroke) showed no statistical difference 
(p=0.1347) when compared to vehicle control using t-test with Welch’s correction for the 
drug group. (C). Direct comparison of infarct volumes between early and delayed treatment 
groups that indicates significant difference using t-test with Welch’s correction (15.4 ± 
4.260 mm3 SEM, p =0.0157), with the earlier delivery time producing a much larger infarct.  
Each dot represents an animal in each group. The x-axis displays treatment groups, and 
the y-axis shows the infarct volume in mm3. The broad horizontal bar indicates the 
group mean and the error bars represent SEM, with individual infarct volumes given by 
closed symbols clustered around means. 
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Impact of Physical Rehabilitation on Motor Recovery 
Another limitation for a successful translation between experimental studies and 
clinical research is the usefulness of the rehabilitation procedure and time. Appropriate and 
adequate physical rehabilitation is essential to ensuring effective improvement of post-
stroke motor recovery in a rodent model. To obtain reliable data, the chosen method of 
physical rehabilitation we utilized was performed with minimum stress and anxiety to the 
animals. Our findings indicate that the drug combination (fluoxetine and simvastatin) 
treatment in female Sprague-Dawley rats achieved slightly greater motor functional 
recovery in rehabilitated animals compared to rehabilitated vehicle-treated animals. 
Rehabilitation did not improve the overall functional recovery seen in the drug treated 
animals, but it did seem to speed the overall recovery, with drug combination only 
providing a slower steady progression.  This drug treatment, however, may provide 
adequate recovery for human stroke patients who cannot participate in physical 
rehabilitation. 
The Anti-inflammatory Role of the Drug Combination 
The combination therapy of fluoxetine and simvastatin reveals promising signs of 
a neuroprotective role in inflammation through inducing anti-inflammatory markers and 
suppressing the pro-inflammatory ones. Studies have shown that activated microglia can 
act as a double-edged sword to detrimentally intensify neurotoxicity when inflammatory 
markers are high (Levesque et al., 2010), (Harry & Kraft, 2008), or potentially promoting 
neuronal regeneration and recovery when they are changed into M2 type microglia (Diestel 
et al., 2010), (McPherson, Kraft, & Harry, 2011). These contradictory effects come from 
diverse experimental sets of in vitro and in vivo models that vary in terms of the activation 
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stimulus, timing of microglial activation, sex and age of animals (Luo & Chen, 2012). Our 
preliminary data has indicated that at post-stroke day 7, the microglia is primarily in the 
M2 form, however, as a recent review of neuroinflammation indicates that microglia 
undergoes a broad range of morphological transformations in a time-dependent fashion 
(Fumagalli, Perego, Pischiutta, Zanier, & De Simoni, 2015), microglia express M1 markers 
in the very early phases after injury followed by recruitment of macrophages and 
expression of M2 markers by both myeloid populations. The peak of M2 marker expression 
rapidly disappears and is followed by another upregulation of M1 markers that persists 
longer. The cells also undergo morphological changes from sprouting ramified cells soon 
after brain injury to non-branching phenotype followed by phagocytic ameboid shape few 
days after the initial brain insult (Xiang, Haroutunian, Ho, Purohit, & Pasinetti, 2006).  
Our customized array contains microglia markers to pro-inflammatory M1 and anti-
inflammatory M2 subtypes that have been discussed in literature; however, we do not know 
whether these markers are sufficient to distinguish between the different types of microglia 
in our animal models. There are some troubling signs, like up-regulation of some markers 
and down-regulation of other markers for the same microglial subtype, which require 
further investigation. As it has been previously reported, after focal cerebral ischemia, 
microglia are activated rapidly in response to brain damage and their proliferation peaks 
within 2 to 3 days of ischemia onset (Lalancette-Hebert, Gowing, Simard, Weng, & Kriz, 
2007). We might miss the opportunity to explore the early stage changes in microglia 
activity by delaying the evaluation of microglia markers to post-stroke day 7. In future 
studies, we will need to test an earlier time point, perhaps 48 to 72 hours post-stroke to see 
any potential differences in the M1 and M2 microglial subtypes. 
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There is a possibility that expression of microglia markers may vary with animal’s 
age and sex. Our findings indicate variable effects of the drug combination on gene 
expression by microglial subtypes in male and female animals. For example; treating male 
rats with the combination drug significantly led to significant up-regulation of two pro-
inflammatory markers of M1 microglia, Ccl11 and Stat4, while also showing reduced  
expression of a tryptophan metabolism effector molecule Nos2, which is another M1 pro-
inflammatory marker. Female rats, on the other hand, show a different pattern of response 
to drug treatment; the significant up-regulation of the sex determining region Y-box 2 
(Sox2) gene in female rats may provide a sign of a sex-dependent role of the drug on 
microglial gene upregulation. The SOX2 transcription factor is critical for maintaining self-
renewal of embryonic and neural stem cells (Rizzino, 2009). The drug combination 
exhibits a trend of up-regulation of the anti-inflammatory marker of M2a and M2c 
microglia, Bdnf, with a 3.85 fold change in male rats; whereas when female rats treated 
with the same combination drug the fold change of Bdnf was 1.99. These findings suggest 
a possible sex-dependent effect of the medicine that needs to be confirmed by increasing 
the number of tested animals. 
Interestingly, prior and post-treatment of male Sprague-Dawley rats with 
simvastatin only demonstrates that simvastatin by itself has no inhibitory effect on pro-
inflammatory cytokines as fluoxetine does. This outcome proposes a vital role of fluoxetine 
in the FSA drug combination in down-regulating the pro-inflammatory genes. 
Effects of the Drug Combination on Neurotrophic Factors and Synaptic Plasticity 
Our results imply a positive effect of the drug combination in stimulating 
neurotrophic factors and synaptic plasticity genes. The sex-specific pattern of gene 
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expression varies between male and female rats receiving the same dose of fluoxetine, 
simvastatin, and ascorbic acid treatment at the same time.  
An interesting finding in neurotrophic factors expression profile indicates 
remarkable upregulation of orexin/hypocretin (HCRT) protein in male drug treatment 
group of rats, with a trend toward significance (9.92 fold regulation). These results were 
similar to what we have seen before in female rats. Our previous work on adult female rats 
treated with the same dose of drug combination for 10 days after stroke showed that orexin 
was upregulated to 2.06 fold, while another experiment that used fluoxetine and 
simvastatin (FS) only for the same amount of time in adult female rats showed  significant 
upregulation of Hctr1 (2.07) and Hctr2 (2.93); p <0.05. In light of these findings, 
endogenous HcRt may mediate the neuroprotective effect of the FSA drug combination 
and contribute to its beneficial role in motor recovery in male rats. The exact mechanisms 
of action of HcRt though are not clear. In Figure 45 of protein-protein interaction network, 
it appears that the orexin pathway ( Hcrt and Hcrtr1 and Hcrtr2) would work through 
neuropeptide Y Npy and its receptor Npy1r, that are known for their significant role in 
hippocampal learning and memory (Howell et al., 2003), to boost synaptic plasticity. 
Further studies are required to elucidate these mechanisms.  
Another critical finding was the down-regulation of matrix metalloprotease gene 
(Mmp9) in male rats treated with FSA combination. This gene encodes a protein that is 
responsible for degrading the extracellular matrix proteins and involved in blood-brain-
barrier damage after ischemic stroke. A previous in vivo study on adult mice from another 
laboratory demonstrated an inhibitory role of fluoxetine in Mmp9 regulation. 
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A significant down-regulation of the apoptotic gene, Fas (TNF receptor 
superfamily, member 6) in adult male rats treated with FSA in compare to control animals 
(p=0.031) provide preliminary evidence of possible anti-apoptotic role of the drug 
combination in suppressing this gene that is involved in negative regulation of cell death, 
apoptotic process and TNF signaling pathway.  
Utilizing the STRING software to predict protein-protein interactions and 
demonstrate how genes cluster in individual pathways, enables a previously unobtainable 
level of visualization of the regulated genes in the pathophysiology of stroke. The predicted 
analyses depict gene networks that interact mainly in signal transduction, cell-cell 
signaling, regulation of multicellular organismal process, cellular response to stimulus, 
nervous system development, cell differentiation and proliferation, positive regulation of 
biological process and receptor binding. Up-regulating of these genes in response to FSA 
drug treatment may indicate a potential role of the drug in inducing neurotrophic factors 
critical for neurogenesis and motor recovery after stroke.  
To better understand mechanisms that promote recovery after ischemic stroke and 
to evaluate the effect of pharmacologic interventions, future studies should continue to 
investigate the relationship between molecular data (neurotrophic factors and brain tissue 
plasticity), histopathological analysis (infarct volume and hemorrhagic transformation) as 
well as behavioral outcome; with emphasis on investigating early genetic changes in 
different sexes for their effect long-term functional recovery.  These data suggest that 











 CONCLUSIONS AND FUTURE DIRECTIONS 
 
1). Giving Fluoxetine 20-26 hours after stroke induction not only promotes functional 
motor recovery but also reduces the infarct volume significantly compared to giving the 
Fluoxetine within 6-12hrs of stroke induction. Waiting for 48hours before giving the 
treatment did not have any beneficial effect on infarct size.  
2). Counting only the numbers of touches made by palmar pads is a more sensitive 
behavioral analysis of functional deficit than including amounts of contacts made by both 
palmar pads and fingertips. 
3). Rehabilitation speeds recovery post-stroke when there is drug treatment, but we are able 
to achieve the same level of recovery with our drug treatment without rehabilitation.   
4) We see differences in the upregulation and down regulation of genes in female rats 
compared to male rats following stroke, with better recovery seen with a slightly different 
drug combination. 
5). Gene analysis shows upregulation of neurotrophic factors and synaptic plasticity genes 
in FSA males, pointing to a possibly important upregulation of orexin receptors, which 
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Gene table shows gene position, symbol and description for M1 and M2 microglia 
biomarkers. 
 
A01 Bdnf Brain-derived neurotrophic factor 
A02 Arg1 Arginase 
A03 Camk2a Calcium/calmodulin-dependent protein kinase II alpha 
A04 Camk2g Calcium/calmodulin-dependent protein kinase II gamma 
A05 Cbln1 Cerebellin 1 precursor 
A06 Ccl11 Chemokine (C-C motif) ligand 11 
A07 Bdnf Brain-derived neurotrophic factor 
A08 Arg1 Arginase 
A09 Camk2a Calcium/calmodulin-dependent protein kinase II alpha 
A10 Camk2g Calcium/calmodulin-dependent protein kinase II gamma 
A11 Cbln1 Cerebellin 1 precursor 
A12 Ccl11 Chemokine (C-C motif) ligand 11 
B01 Cd163 CD163 molecule 
B02 Cd40 CD40 molecule, TNF receptor superfamily member 5 
B03 Cntf Ciliary neurotrophic factor 
B04 Cntfr Ciliary neurotrophic factor receptor 
B05 Creb1 CAMP responsive element binding protein 1 
B06 Crh Corticotropin releasing hormone 
B07 Cd163 CD163 molecule 
B08 Cd40 CD40 molecule, TNF receptor superfamily member 5 
B09 Cntf Ciliary neurotrophic factor 
B10 Cntfr Ciliary neurotrophic factor receptor 
B11 Creb1 CAMP responsive element binding protein 1 
B12 Crh Corticotropin releasing hormone 
C01 Crhbp Corticotropin releasing hormone binding protein 
C02 Crhr1 Corticotropin releasing hormone receptor 1 
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C03 Crhr2 Corticotropin releasing hormone receptor 2 
C04 Cxcr4 Chemokine (C-X-C motif) receptor 4 
C05 Fgf9 Fibroblast growth factor 9 
C06 Fos FBJ osteosarcoma oncogene 
C07 Crhbp Corticotropin releasing hormone binding protein 
C08 Crhr1 Corticotropin releasing hormone receptor 1 
C09 Crhr2 Corticotropin releasing hormone receptor 2 
C10 Cxcr4 Chemokine (C-X-C motif) receptor 4 
C11 Fgf9 Fibroblast growth factor 9 
C12 Fos FBJ osteosarcoma oncogene 
D01 Galr1 Galanin receptor 1 
D02 Gfra3 GDNF family receptor alpha 3 
D03 Gmfg Glia maturation factor, gamma 
D04 Il1b Interleukin 1 beta 
D05 il10ra Interleukin 10 receptor, alpha 
D06 Il6 Interleukin 6 
D07 Galr1 Galanin receptor 1 
D08 Gfra3 GDNF family receptor alpha 3 
D09 Gmfg Glia maturation factor, gamma 
D10 Il1b Interleukin 1 beta 
D11 il10ra Interleukin 10 receptor, alpha 
D12 Il6 Interleukin 6 
E01 Nos2 Nitric oxide synthase 2, inducible 
E02 Nell1 NEL-like 1  
E03 Npy1r Neuropeptide Y receptor Y1 
E04 Npy2r Neuropeptide Y receptor Y2 
E05 Sox2 SRY (sex determining region Y)-box 2 
E06 Stat1 Signal transducer and activator of transcription 1 
E07 Nos2 Nitric oxide synthase 2, inducible 
E08 Nell1 NEL-like 1  
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E09 Npy1r Neuropeptide Y receptor Y1 
E10 Npy2r Neuropeptide Y receptor Y2 
E11 Sox2 SRY (sex determining region Y)-box 2 
E12 Stat1 Signal transducer and activator of transcription 1 
F01 Stat3 Signal transducer and activator of transcription 3 
F02 Stat4 Signal transducer and activator of transcription 4 
F03 Stat6 Signal transducer and activator of transcription 6 
F04 Tgfb1 Transforming growth factor, beta 1 
F05 Tnf Tumor necrosis factor (TNF superfamily, member 2) 
F06 Plat Plasminogen activator, tissue 
F07 Stat3 Signal transducer and activator of transcription 3 
F08 Stat4 Signal transducer and activator of transcription 4 
F09 Stat6 Signal transducer and activator of transcription 6 
F10 Tgfb1 Transforming growth factor, beta 1 
F11 Tnf Tumor necrosis factor (TNF superfamily, member 2) 
F12 Plat Plasminogen activator, tissue 
G01 Grip1 Glutamate receptor interacting protein 1 
G02 Vegfa Vascular endothelial growth factor A 
G03 Ppih Peptidylprolyl isomerase H (cyclophilin H) 
G04 Actb Actin, beta 
G05 Hprt1 Hypoxanthine phosphoribosyltransferase 1 
G06 Ldha Lactate dehydrogenase A 
G07 Grip1 Glutamate receptor interacting protein 1 
G08 Vegfa Vascular endothelial growth factor A 
G09 Ppih Peptidylprolyl isomerase H (cyclophilin H) 
G10 Actb Actin, beta 
G11 Hprt1 Hypoxanthine phosphoribosyltransferase 1 
G12 Ldha Lactate dehydrogenase A 
H01 Nono Non-POU domain containing, octamer-binding 
H02 GDC  Genomic DNA control 
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H03 RTC   Reverse-transcription control 
H04 RTC   Reverse-transcription control 
H05 PPC   Positive PCR control 
H06 PPC   Positive PCR control 
H07 Nono Non-POU domain containing, octamer-binding 
H08 GDC   Genomic DNA control 
H09  RTC   Reverse-transcription control 
H10  RTC   Reverse-transcription control 
H11  PPC   Positive PCR control 



















Gene table shows gene position, symbol and description for neurotrophins and 
receptors RT² Profiler PCR Array    
A01 Adcyap1r1 Adenylate cyclase activating polypeptide 1 receptor 1 
A02 Artn Artemin 
A03 Bax Bcl2-associated X protein 
A04 Bcl2 B-cell CLL/lymphoma 2 
A05 Bdnf Brain-derived neurotrophic factor 
A06 Cbln1 Cerebellin 1 precursor 
A07 Cckar Cholecystokinin A receptor 
A08 Cd40 CD40 molecule, TNF receptor superfamily member 5 
A09 Cntf Ciliary neurotrophic factor 
A10 Cntfr Ciliary neurotrophic factor receptor 
A11 Crh Corticotropin releasing hormone 
A12 Crhbp Corticotropin releasing hormone binding protein 
B01 Crhr1 Corticotropin releasing hormone receptor 1 
B02 Crhr2 Corticotropin releasing hormone receptor 2 
B03 Cx3cr1 Chemokine (C-X3-C motif) receptor 1 
B04 Cxcr4 Chemokine (C-X-C motif) receptor 4 
B05 Fas Fas (TNF receptor superfamily, member 6) 
B06 Fgf2 Fibroblast growth factor 2 
Fgf9 Fibroblast growth factor 9 
B08 Fgfr1 Fibroblast growth factor receptor 1 
B09 Fos FBJ osteosarcoma oncogene 
B10 Frs2 Fibroblast growth factor receptor substrate 2 
B11 Frs3 Fibroblast growth factor receptor substrate 3 
B12 Fus Fusion (involved in t(12;16) in malignant liposarcoma) (human) 
C01 Galr1 Galanin receptor 1 
C02 Galr2 Galanin receptor 2 
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C03 Gdnf Glial cell derived neurotrophic factor 
C04 Gfra1 GDNF family receptor alpha 1 
C05 Gfra2 GDNF family receptor alpha 2 
C06 Gfra3 GDNF family receptor alpha 3 
C07 Gmfb Glia maturation factor, beta 
C08 Gmfg Glia maturation factor, gamma 
C09 Grpr Gastrin releasing peptide receptor 
C10 HcRt Hypocretin 
C11 Hcrtr1 Hypocretin (orexin) receptor 1 
C12 Hcrtr2 Hypocretin (orexin) receptor 2 
D01 Hspb1 Heat shock protein 1 
D02 Il10 Interleukin 10 
D03 Il10ra Interleukin 10 receptor, alpha 
D04 Il1b Interleukin 1 beta 
D05 Il1r1 Interleukin 1 receptor, type I 
D06 Il6 Interleukin 6 
D07 Il6r Interleukin 6 receptor 
D08 Il6st Interleukin 6 signal transducer 
D09 Lif Leukemia inhibitory factor 
D10 Lifr Leukemia inhibitory factor receptor alpha 
D11 Maged1 Melanoma antigen, family D, 1 
D12 Mc2r Melanocortin 2 receptor 
E01 Mt3 Metallothionein 3 
E02 Myc Myelocytomatosis oncogene 
E03 Nell1 NEL-like 1  
E04 Nf1 Neurofibromin 1 
E05 Ngf Nerve growth factor (beta polypeptide) 
E06 Ngfr Nerve growth factor receptor (TNFR superfamily, member 16) 
E07 Ngfrap1 Nerve growth factor receptor (TNFRSF16) associated protein 1 
E08 Npffr2 Neuropeptide FF receptor 2 
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E09 Npy Neuropeptide Y 
E10 Npy1r Neuropeptide Y receptor Y1 
E11 Npy2r Neuropeptide Y receptor Y2 
E12 Nr1i2 Nuclear receptor subfamily 1, group I, member 2 
F01 Nrg1 Neuregulin 1 
F02 Nrg2 Neuregulin 2 
F03 Ntf3 Neurotrophin 3 
F04 Ntf4 Neurotrophin 4 
F05 Ntrk1 Neurotrophic tyrosine kinase, receptor, type 1 
F06 Ntrk2 Neurotrophic tyrosine kinase, receptor, type 2 
F07 Ntsr1 Neurotensin receptor 1 
F08 Ppyr1 Pancreatic polypeptide receptor 1 
F09 Pspn Persephin 
F10 Ptger2 Prostaglandin E receptor 2 (subtype EP2) 
F11 Stat1 Signal transducer and activator of transcription 1 
F12 Stat2 Signal transducer and activator of transcription 2 
G01 Stat3 Signal transducer and activator of transcription 3 
G02 Stat4 Signal transducer and activator of transcription 4 
G03 Tacr1 Tachykinin receptor 1 
G04 Tfg Trk-fused gene 
G05 Tgfa Transforming growth factor alpha 
G06 Tgfb1 Transforming growth factor, beta 1 
G07 Tgfb1i1 Transforming growth factor beta 1 induced transcript 1 
G08 Tp53 Tumor protein p53 
G09 Ucn Urocortin 
G10 Vgf VGF nerve growth factor inducible 
G11 Zfp110 Zinc finger protein 110 
G12 Zfp91 Zinc finger protein 91 
H01 Actb Actin, beta 
H02 B2m Beta-2 microglobulin 
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H03 Hprt1 Hypoxanthine phosphoribosyltransferase 1 
H04 Ldha Lactate dehydrogenase A 
H05 Rplp1 Ribosomal protein, large, P1 
H06 RGDC Rat Genomic DNA Contamination 
H07 RTC Reverse Transcription Control 
H08 RTC Reverse Transcription Control 
H09 RTC Reverse Transcription Control 
H10 PPC Positive PCR Control 
H11 PPC Positive PCR Control 

























Gene table shows gene position, symbol and description for synaptic plasticity RT² 
Profiler PCR Array. 
A01 Adam10 ADAM metallopeptidase domain 10 
A02 Adcy1 Adenylate cyclase 1 (brain) 
A03 Adcy8 Adenylate cyclase 8 (brain) 
A04 Akt1 V-akt murine thymoma viral oncogene homolog 1 
A05 Arc Activity-regulated cytoskeleton-associated protein 
A06 Bdnf Brain-derived neurotrophic factor 
A07 Camk2a Calcium/calmodulin-dependent protein kinase II alpha 
A08 Camk2g Calcium/calmodulin-dependent protein kinase II gamma 
A09 Cdh2 Cadherin 2 
A10 Cebpb CCAAT/enhancer binding protein (C/EBP), beta 
A11 Cebpd CCAAT/enhancer binding protein (C/EBP), delta 
A12 Cnr1 Cannabinoid receptor 1 (brain) 
B01 Creb1 CAMP responsive element binding protein 1 
B02 Crem CAMP responsive element modulator 
B03 Dlg4 Discs, large homolog 4 (Drosophila) 
B04 Egr1 Early growth response 1 
B05 Egr2 Early growth response 2 
B06 Egr3 Early growth response 3 
B07 Egr4 Early growth response 4 
B08 Ephb2 Eph receptor B2 
B09 Fos FBJ osteosarcoma oncogene 
B10 Gabra5 Gamma-aminobutyric acid (GABA) A receptor, alpha 5 
B11 Gnai1 Guanine nucleotide binding protein (G protein), alpha inhibiting 1 
B12 Gria1 Glutamate receptor, ionotropic, AMPA 1 
C01 Gria2 Glutamate receptor, ionotropic, AMPA 2 
C02 Gria3 Glutamate receptor, ionotrophic, AMPA 3 
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C03 Gria4 Glutamate receptor, ionotrophic, AMPA 4 
C04 Grin1 Glutamate receptor, ionotropic, N-methyl D-aspartate 1 
C05 Grin2a Glutamate receptor, ionotropic, N-methyl D-aspartate 2A 
C06  Grin2b Glutamate receptor, ionotropic, N-methyl D-aspartate 2B 
C07  Grin2c Glutamate receptor, ionotropic, N-methyl D-aspartate 2C 
C08 Grin2d Glutamate receptor, ionotropic, N-methyl D-aspartate 2D 
C09 Grip1 Glutamate receptor interacting protein 1 
C10 Grm1 Glutamate receptor, metabotropic 1 
C11 Grm2 Glutamate receptor, metabotropic 2 
C12 Grm3 Glutamate receptor, metabotropic 3 
D01 Grm4 Glutamate receptor, metabotropic 4 
D02 Grm5 Glutamate receptor, metabotropic 5 
D03 Grm7 Glutamate receptor, metabotropic 7 
D04 Grm8 Glutamate receptor, metabotropic 8 
D05 Homer1 Homer homolog 1 (Drosophila) 
D06 Igf1 Insulin-like growth factor 1 
D07 Inhba Inhibin beta-A 
D08 Jun Jun oncogene 
D09 Junb Jun B proto-oncogene 
D10 Kruppel-like factor 10 
D11 Mapk1 Mitogen activated protein kinase 1 
D12 Mmp9 Matrix metallopeptidase 9 
E01 Ncam1 Neural cell adhesion molecule 1 
E02 Nfkb1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 
E03 Nfkbib Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, beta 
E04 Ngf Nerve growth factor (beta polypeptide) 
E05 Ngfr Nerve growth factor receptor (TNFR superfamily, member 16) 
E06 Nos1 Nitric oxide synthase 1, neuronal 
E07 Nptx2 Neuronal pentraxin 2 
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E08  Nr4a1 Nuclear receptor subfamily 4, group A, member 1 
E09  Ntf3 Neurotrophin 3 
E10 Ntf4 Neurotrophin 4 
E11 Ntrk2 Neurotrophic tyrosine kinase, receptor, type 2 
E12 Pcdh8 Protocadherin 8 
F01 Pick1 Protein interacting with PRKCA 1 
F02 Pim1 Pim-1 oncogene 
F03 Plat Plasminogen activator, tissue 
F04 Plcg1 Phospholipase C, gamma 1 
F05 Ppp1ca Protein phosphatase 1, catalytic subunit, alpha isoform 
F06 Ppp1cc Protein phosphatase 1, catalytic subunit, gamma isoform 
F07 Ppp1r14a Protein phosphatase 1, regulatory (inhibitor) subunit 14A 
F08 Ppp2ca Protein phosphatase 2, catalytic subunit, alpha isoform 
F09 Ppp3ca Protein phosphatase 3, catalytic subunit, alpha isoform 
F10 Prkca Protein kinase C, alpha 
F11 Prkcg Protein kinase C, gamma 
F12 Prkg1 Protein kinase, cGMP-dependent, type 1 
G01 Rab3a RAB3A, member RAS oncogene family 
G02 Rela V-rel reticuloendotheliosis viral oncogene homolog A (avian) 
G03 Reln Reelin 
G04 RGD1562511 Similar to MmKIF17 
G05 Rgs2 Regulator of G-protein signaling 2 
G06 Rheb Ras homolog enriched in brain 
G07 Sirt1 Sirtuin (silent mating type information regulation 2 homolog) 1 (S. 
cerevisiae) 
G08 Srf Serum response factor (c-fos serum response element-binding transcription 
factor) 
G09 Synpo Synaptopodin 
G10 Timp1 TIMP metallopeptidase inhibitor 1 theta polypeptide 
H01 Actb Actin, beta 
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H02 B2m Beta-2 microglobulin 
H03 Hprt1 Hypoxanthine phosphoribosyltransferase 1 
H04 Ldha Lactate dehydrogenase A 
H05 Rplp1 Ribosomal protein, large, P1 
H06 RGDC Rat Genomic DNA Contamination 
H07 RTC Reverse Transcription Control 
H08 RTC Reverse Transcription Control 
H09 RTC Reverse Transcription Control 
H10 PPC Positive PCR Control 
H11 PPC Positive PCR Control 























Neurotrophins & Receptors PCR Array:  Functional Gene Grouping 
Neuropeptides and Receptors: 
Adcyap1r1, Artn, Bdnf, Cntf, Cntfr, Crh, Crhbp, Crhr1, Crhr2, Frs2, Frs3, Gdnf, Gfra1, 
Gfra2, Gfra3, Gmfb, Gmfg, Hcrtr1, Hcrtr2, Mt3, Ngf, Ngfr, Ngfrap1, Nr1i2, Nrg1 (Hgl), 
Nrg2, Ntf3, Ntf4, Ntrk1, Ntrk2, Pspn, Ptger2, Tfg, Cd40 (Tnfrsf5), Fas (Tnfrsf6), Ucn, 
Vgf, Zfp110, Zfp91. 
Neuropeptides and Receptors: 
Galanin Receptors: Galr1, Galr2. 
Neuropeptide Y Receptors: Npy1r, Npy2r, Npy4r. 
Other Neuropeptides and Receptors: Cckar, Grpr, Npffr2 (Gpr74), Ntsr1, HcRt, Mc2r, 
Npy, Nrg1 (Hgl), Tacr1. 
Neurogenesis:  
Central Nervous System Development: Cxcr4, Fgfr1, Ngfr, Ntf3. 
Peripheral Nervous System Development: Artn, Gdnf, Gfra3, Ngf, Nrg1 (Hgl), Ntf3. 
Axon Guidance: Artn, Gfra3, Ngfr. 
Gliogenesis: Fgf2 (bFGF), Nrg1 (Hgl), Ntf3. 
Dendrite Morphogenesis: Bdnf, Mt3. 
Other Neurogenesis Genes: Bax, Fos, Cbln1, Galr2, Gfra1, Gfra2, Nell1, Ntf4, Ntrk1, 
Ntrk2. 
Cell Growth and Differentiation:  
Growth Factors and Receptors: Artn, Bdnf, Fgf2 (bFGF), Fgf9, Fgfr1, Gdnf, Gmfb, Gmfg, 
Il10, Il1b, Il6, Lif, Mt3, Ngf, Nrg2, Ntf3, Ntf4, Pspn, Tgfa, Tgfb1, Tgfb1i1, Tp53, Vgf. 
Cell Cycle: Fgf2 (bFGF), Fgf9, Il1b, Ntrk1, Tgfa, Tgfb1, Tp53. 




Cell Differentiation: Cntf, Fgf2 (bFGF), Fgf9, Nf1, Nrg1 (Hgl), Stat3, Tp53, Zfp91. 
Cytokines and Receptors:  
Cx3cr1, Cxcr4, Il10, Il10ra, Il1b, Il1r1, Il6, Il6r, Il6st (Gp130), Lif, Lifr,. 
Apoptosis: 
 Bax, Bcl2, Cd40 (Tnfrsf5), Hspb1 (Hsp27), Il10, Il6, Myc, Ngfr, Ngfrap1, Fas (Tnfrsf6), 
Tp53. 
Inflammatory Response:  
Il10, Il1b, Il6, Stat3, Tgfb1. 
Immune Response: 
 Il10, Cd40 (Tnfrsf5), Lif, Fas (Tnfrsf6). 
Transcription Factors and Regulators:  
 



















Rat Synaptic Plasticity PCR Array: Functional Gene Grouping 
Immediate-Early Response Genes (IEGs):  
Arc, Bdnf, Cebpb, Cebpd, Creb1, Crem, Egr1, Egr2, Egr3, Egr4, Fos, Homer1, Jun, 
Junb, Klf10, Mmp9 (Gelatinase B), Nfkb1, Nfkbib (Trip9), Ngf, Nptx2, Nr4a1, Ntf3, 
Pcdh8, Pim1, Plat (tPA), Rela, Rgs2, Rheb, Srf, Tnf.  
Late Response Genes: Inhba, Synpo.  
Long Term Potentiation (LTP): Adcy1, Adcy8, Bdnf, Camk2a, Camk2g, Cdh2 (N-
cadherin), Cnr1, Gabra5, Gnai1, Gria1, Gria2, Grin1, Grin2a, Grin2b, Grin2c, Grin2d, 
Mapk1, Mmp9 (Gelatinase B), Ntf4, Ntrk2, Plcg1, Ppp1ca, Ppp1cc, Ppp3ca, Prkca, 
Prkcg, Rab3a, Ywhaq (14-3-3).  
Long Term Depression (LTD): Gnai1, Gria1, Gria2, Gria3, Gria4, Grip1, Grm1, 
Grm2, Igf1, Mapk1, Nos1, Ngfr, Pick1, Plat (tPA), Ppp1ca, Ppp1cc, Ppp1r14a (Cpi-17), 
Ppp2ca, Ppp3ca, Prkca, Prkg1.  
Cell Adhesion: Adam10, Cdh2 (N-cadherin), Grin2a, Grin2b, Ncam1, Pcdh8, Ppp2ca, 
Reln, Tnf.  
Extracellular Matrix & Proteolytic Processing: Adam10, Mmp9 (Gelatinase B), Plat 
(tPA), Reln, Timp1.  
CREB Cofactors: Akt1, Camk2g, Grin1, Grin2a, Grin2b, Grin2c, Grin2d, Mapk1 
(Erk2), Ppp1ca, Ppp1cc.  
Neuronal Receptors: Ephb2, Gabra5, Gria1, Gria2, Gria3, Gria4, Grin1, Grin2a, 
Grin2b, Grin2c, Grin2d, Grm1, Grm2, Grm3, Grm4, Grm5, Grm7, Grm8, Ntrk2. 
Postsynaptic Density: Adam10, Arc, Dlg4 (Psd95), Gria1, Gria3, Gria4, Grin1, Grin2a, 




Fold Chang and Fold Regulation Values 
Tables below show data from RT2 PCR including gene symbol, p-value, fold 
change and fold regulation. Data are sorted by p-value from lowest to highest.  Fold-change 
and fold-regulation values greater than 2 are indicated in red; fold-change values less than 
0.5 and fold-regulation values less than -2 are indicated in blue. 
A. FSA-treated Male Rats Comparing to Control Male Rats 
Gene Symbol p-value fold change  fold regulation 
Ccl11 0.03234 3.7352 3.7352 
Stat4 0.041333 2.0813 2.0813 
Bdnf 0.089873 3.851 3.851 
Nos2 0.094423 0.50001 -2.0004 
Crhbp 0.158613 1.6378 1.6378 
Nell1 0.227599 1.2708 1.2708 
Cbln1 0.280965 1.8809 1.8809 
Arg1 0.291588 0.7505 -1.3325 
Crh 0.35071 1.4626 1.4626 
Cntfr 0.423522 0.874 -1.1442 
Galr1 0.436634 1.1068 1.1068 
Sox2 0.534786 0.8478 -1.1795 
Creb1 0.550981 0.719 -1.3908 
Il1b 0.554228 0.5653 -1.7691 
Npy2r 0.566378 1.0393 1.0393 
Vegfa 0.589248 0.9202 -1.0867 
Cd163 0.633102 0.995 -1.0051 
Camk2a 0.673144 0.8677 -1.1525 
Fgf9 0.719273 1.019 1.019 
Crhr1 0.721574 0.956 -1.046 
Grip1 0.754236 0.9615 -1.04 
Npy1r 0.75501 0.9634 -1.038 
Il6 0.760602 0.6318 -1.5827 
Cd40 0.771506 0.7912 -1.264 
Gmfg 0.771657 0.7572 -1.3206 
Camk2g 0.774906 0.9605 -1.0411 
Tnf 0.785379 0.617 -1.6207 
Gfra3 0.828051 0.4734 -2.1123 
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Cntf 0.850348 0.8518 -1.1739 
Stat1 0.851229 0.6064 -1.649 
Stat3 0.895215 1.0923 1.0923 
il10ra 0.895902 0.8025 -1.246 
Crhr2 0.953413 0.897 -1.1148 
Fos 0.971686 1.0238 1.0238 
Plat 0.972077 0.9203 -1.0866 
Tgfb1 0.97797 0.6633 -1.5077 
Cxcr4 0.991455 0.6021 -1.6608 

























B. FSA-treated Female Rats Comparing to Control Female Rats 
Gene Symbol p-value fold change  fold regulation 
Sox2 0.047631 2.5115 2.5115 
Cntf 0.057901 1.6898 1.6898 
Creb1 0.059055 1.4316 1.4316 
Fos 0.076262 1.3918 1.3918 
Cntfr 0.099695 1.7101 1.7101 
Crhr2 0.101033 1.4342 1.4342 
Crhr1 0.10333 2.4755 2.4755 
Camk2g 0.125511 2.1039 2.1039 
Crh 0.147916 2.3538 2.3538 
Arg1 0.155278 0.3795 -2.6353 
Galr1 0.155288 1.7544 1.7544 
Plat 0.165041 1.3647 1.3647 
il10ra 0.202232 1.4973 1.4973 
Crhbp 0.215802 2.2195 2.2195 
Fgf9 0.225599 1.8046 1.8046 
Gfra3 0.253349 1.3295 1.3295 
Bdnf 0.272128 1.9904 1.9904 
Cbln1 0.310568 2.0208 2.0208 
Vegfa 0.337747 1.2386 1.2386 
Camk2a 0.351778 1.8665 1.8665 
Stat4 0.356739 1.3098 1.3098 
Stat1 0.362456 1.1966 1.1966 
Npy2r 0.367681 1.4132 1.4132 
Il6 0.3708 0.7732 -1.2933 
Tgfb1 0.378224 1.487 1.487 
Grip1 0.379007 1.3269 1.3269 
Ccl11 0.395425 1.2771 1.2771 
Nell1 0.412523 2.1142 2.1142 
Cd163 0.4487 1.2084 1.2084 
Nos2 0.536738 0.8217 -1.217 
Npy1r 0.57088 1.425 1.425 
Tnf 0.638525 1.0934 1.0934 
Cd40 0.63938 1.1124 1.1124 
Stat3 0.646504 1.0171 1.0171 
Gmfg 0.715201 0.7491 -1.335 
Stat6 0.811588 1.1616 1.1616 
Il1b 0.824719 0.974 -1.0267 




C. Simvastatin-treated Male Rats Comparing to Control Male Rats 
Gene Symbol p-value fold change  fold regulation 
Ccl11 0.022319 2.3405 2.3405 
Crhr2 0.067797 1.4184 1.4184 
Cd163 0.073125 1.7696 1.7696 
Fos 0.167572 1.3642 1.3642 
Nos2 0.181671 0.7392 -1.3528 
Cbln1 0.185183 2.0057 2.0057 
Galr1 0.19592 1.4718 1.4718 
Bdnf 0.200537 3.0055 3.0055 
Crhbp 0.222841 1.4558 1.4558 
Stat6 0.223868 1.6405 1.6405 
Plat 0.256844 1.1847 1.1847 
Cntf 0.2591 1.412 1.412 
Cntfr 0.264005 1.1983 1.1983 
Tgfb1 0.275765 1.4401 1.4401 
il10ra 0.292258 1.6629 1.6629 
Camk2a 0.30005 1.2253 1.2253 
Sox2 0.316827 1.2873 1.2873 
Camk2g 0.327571 1.1834 1.1834 
Grip1 0.346105 1.2544 1.2544 
Il6 0.415327 0.865 -1.1561 
Stat3 0.425231 1.4677 1.4677 
Npy2r 0.426295 1.2733 1.2733 
Cxcr4 0.429465 1.4594 1.4594 
Npy1r 0.441851 1.2411 1.2411 
Cd40 0.489159 1.485 1.485 
Creb1 0.504883 1.1676 1.1676 
Fgf9 0.521157 1.1251 1.1251 
Arg1 0.524046 1.1999 1.1999 
Nell1 0.550677 1.1268 1.1268 
Tnf 0.554736 1.1165 1.1165 
Gmfg 0.574405 1.3142 1.3142 
Crhr1 0.5775 1.0366 1.0366 
Il1b 0.723912 1.1045 1.1045 
Crh 0.824846 0.8641 -1.1573 
Gfra3 0.880793 0.7031 -1.4223 
Stat4 0.918165 1.0875 1.0875 
Vegfa 0.947222 0.9915 -1.0085 




D. FSA-treated Female Rats Comparing to FSA-treated Male Rats 
Gene Symbol p-value fold change  fold regulation 
Fos 0.051224 1.47 1.47 
Gfra3 0.084574 5.8624 5.8624 
Cd163 0.089223 3.0674 3.0674 
Cntf 0.105728 2.2289 2.2289 
Il1b 0.150449 3.2735 3.2735 
Cntfr 0.159912 1.4477 1.4477 
Nos2 0.174178 2.371 2.371 
Crhr2 0.194493 1.5751 1.5751 
Sox2 0.199428 1.7685 1.7685 
Crhr1 0.235838 1.6742 1.6742 
Arg1 0.243321 1.9596 1.9596 
Creb1 0.243441 1.7837 1.7837 
Camk2g 0.265644 1.5051 1.5051 
Tnf 0.273191 3.012 3.012 
Tgfb1 0.295521 2.6995 2.6995 
Stat3 0.321568 1.6189 1.6189 
Plat 0.327347 1.5035 1.5035 
Cxcr4 0.346437 3.4937 3.4937 
Stat1 0.352873 2.3304 2.3304 
Ccl11 0.429505 0.6515 -1.5348 
Grip1 0.440118 1.163 1.163 
il10ra 0.464164 2.0297 2.0297 
Cd40 0.487533 2.4509 2.4509 
Vegfa 0.493297 1.133 1.133 
Stat6 0.496305 1.7039 1.7039 
Crhbp 0.51346 1.4907 1.4907 
Gmfg 0.582022 2.2929 2.2929 
Il6 0.639032 2.3906 2.3906 
Camk2a 0.656883 1.4105 1.4105 
Npy2r 0.783806 1.0019 1.0019 
Nell1 0.844901 1.0061 1.0061 
Stat4 0.849211 1.0134 1.0134 
Fgf9 0.873117 1.1626 1.1626 
Galr1 0.885226 1.3016 1.3016 
Npy1r 0.887996 1.0873 1.0873 
Cbln1 0.906738 0.6692 -1.4944 
Crh 0.910133 1.2329 1.2329 




E. Control Female Rats Comparing to Control Male Rats 
Gene Symbol p-value fold change  fold regulation 
Sox2 0.046977 0.403 -2.4814 
Cntfr 0.074848 0.4995 -2.0022 
Creb1 0.101809 0.6047 -1.6536 
Vegfa 0.129834 0.5682 -1.76 
Camk2g 0.130036 0.4639 -2.1558 
Fgf9 0.1307 0.4431 -2.2566 
Npy2r 0.151455 0.4974 -2.0105 
Crh 0.162665 0.5171 -1.9337 
Crhr1 0.172162 0.4365 -2.2911 
Grip1 0.213425 0.5689 -1.7579 
Cd163 0.221681 1.7048 1.7048 
Ccl11 0.242341 1.2864 1.2864 
Galr1 0.266493 0.5543 -1.8041 
Npy1r 0.268385 0.4962 -2.0152 
Cntf 0.27722 0.7585 -1.3185 
Crhr2 0.27996 0.665 -1.5038 
Cbln1 0.286772 0.4205 -2.3784 
Stat1 0.306141 0.7972 -1.2544 
Plat 0.317554 0.6844 -1.4611 
Arg1 0.343563 2.6161 2.6161 
Camk2a 0.415672 0.4426 -2.2593 
Nell1 0.443202 0.4082 -2.4496 
il10ra 0.443591 0.7343 -1.3618 
Fos 0.464762 0.7299 -1.3701 
Gfra3 0.537377 1.4092 1.4092 
Cxcr4 0.711004 1.347 1.347 
Gmfg 0.728997 1.5647 1.5647 
Il1b 0.737027 1.2825 1.2825 
Tgfb1 0.815698 0.8128 -1.2303 
Stat4 0.817578 1.087 1.087 
Crhbp 0.834578 0.7425 -1.3468 
Tnf 0.845661 1.1474 1.1474 
Stat6 0.873237 0.8267 -1.2096 
Nos2 0.877283 0.9906 -1.0095 
Bdnf 0.915087 1.6769 1.6769 
Il6 0.969347 1.3186 1.3186 
Stat3 0.989123 1.1736 1.1736 




F. Neurotrophic Factors-regulated Gene Expressions in FSA treated Male Rats 
Comparing to Control 
Gene Symbol p-value fold change  fold regulation 
Gdnf 0.027147 0.5286 -1.8919 
Fas 0.03166 0.4035 -2.4784 
Il1b 0.032286 0.3877 -2.5795 
Nr1i2 0.039786 3.7774 3.7774 
Cntf 0.051449 0.6523 -1.533 
Il10 0.059186 0.4512 -2.2165 
Pspn 0.11014 1.6954 1.6954 
Mt3 0.116473 0.7846 -1.2746 
Zfp91 0.119956 1.4965 1.4965 
Galr2 0.120142 1.5424 1.5424 
HcRt 0.128589 9.9214 9.9214 
Npffr2 0.129714 0.5853 -1.7085 
Grpr 0.132977 2.2403 2.2403 
Lif 0.149851 0.2841 -3.5205 
Hspb1 0.160027 0.3582 -2.7916 
Ucn 0.184827 1.5905 1.5905 
Stat3 0.196704 0.6712 -1.49 
Fus 0.200037 0.7883 -1.2686 
Il6 0.210604 0.3641 -2.7461 
Zfp110 0.210782 1.2478 1.2478 
Hcrtr2 0.212278 1.4767 1.4767 
Nell1 0.235502 1.4848 1.4848 
Cckar 0.237235 0.6939 -1.4411 
Npy 0.251874 1.3044 1.3044 
Crhr2 0.255905 1.4652 1.4652 
Cxcr4 0.260175 0.4393 -2.2765 
Bdnf 0.275876 3.9795 3.9795 
Ntrk1 0.27955 0.7334 -1.3636 
Ntrk2 0.291239 1.3084 1.3084 
Nf1 0.317303 1.2141 1.2141 
Ptger2 0.326239 0.554 -1.8049 
Ngfrap1 0.335346 1.2111 1.2111 
Npy1r 0.336204 1.377 1.377 
Fgf2 0.348263 0.789 -1.2674 
Stat4 0.357587 1.5701 1.5701 
Ngf 0.363967 1.2321 1.2321 
Tgfb1i1 0.369922 1.2762 1.2762 
Lifr 0.375133 1.2643 1.2643 
188 
 
Tp53 0.381005 1.1799 1.1799 
Bax 0.407826 0.6913 -1.4465 
Gfra2 0.414646 1.2027 1.2027 
Frs3 0.439885 1.1153 1.1153 
Cx3cr1 0.452364 0.562 -1.7793 
Cbln1 0.454712 1.6227 1.6227 
Hcrtr1 0.457167 1.1227 1.1227 
Npy4r 0.45726 1.3753 1.3753 
Fgf9 0.481014 0.9783 -1.0222 
Myc 0.490162 0.4904 -2.0393 
Ntf3 0.506506 1.4581 1.4581 
Vgf 0.523186 0.9217 -1.0849 
Fgfr1 0.545401 0.7876 -1.2696 
Frs2 0.566019 1.1046 1.1046 
Crh 0.571825 0.9597 -1.042 
Maged1 0.58919 1.0137 1.0137 
Ntf4 0.591481 0.6727 -1.4865 
Il1r1 0.643553 0.6298 -1.5877 
Il10ra 0.659463 0.5726 -1.7464 
Stat1 0.663928 0.754 -1.3263 
Tgfb1 0.682868 0.7713 -1.2965 
Cntfr 0.690641 0.7825 -1.2779 
Il6r 0.691259 0.6581 -1.5195 
Crhbp 0.696538 0.8017 -1.2473 
Nrg2 0.698461 1.0591 1.0591 
Artn 0.72308 0.8388 -1.1921 
Tacr1 0.730063 1.0187 1.0187 
Il6st 0.736219 0.9564 -1.0456 
Npy2r 0.739882 1.4755 1.4755 
Fos 0.741683 0.8284 -1.2071 
Nrg1 0.743462 0.9605 -1.0412 
Adcyap1r1 0.764325 0.7279 -1.3739 
Galr1 0.779722 0.619 -1.6154 
Cd40 0.785942 0.5142 -1.9447 
Gfra1 0.786957 0.8671 -1.1532 
Ngfr 0.817439 0.7037 -1.4211 
Tfg 0.817747 1.0206 1.0206 
Gmfg 0.828249 0.5432 -1.841 
Mc2r 0.831922 0.8033 -1.2449 
Gmfb 0.883504 0.9415 -1.0621 
Tgfa 0.908245 0.9966 -1.0034 
189 
 
Crhr1 0.923336 0.7899 -1.266 
Stat2 0.932098 0.9141 -1.094 
Gfra3 0.937607 0.5988 -1.6699 
Ntsr1 0.985155 0.8096 -1.2353 
Bcl2 0.995706 0.9074 -1.102 
 
 
F. Synaptic Plasticity-regulated Gene Expression in FSA treated Male Rats 
Comparing to Control 
gene p value fod change fold regulation 
Pim1 0.12664 0.6422 -1.5572 
Klf10 0.151032 0.5412 -1.8478 
Nr4a1 0.167991 1.8715 1.8715 
Mmp9 0.177072 0.4552 -2.1968 
Cebpd 0.186163 0.3841 -2.6035 
Jun 0.192471 0.6844 -1.461 
Pcdh8 0.218854 2.851 2.851 
Timp1 0.219116 0.5087 -1.9657 
Cdh2 0.235217 0.6657 -1.5023 
Ntf3 0.25607 1.555 1.555 
Akt1 0.269585 0.7898 -1.2661 
Sirt1 0.291652 1.1592 1.1592 
Tnf 0.295738 0.5748 -1.7399 
Cebpb 0.308731 0.5608 -1.7832 
Cnr1 0.330611 0.5847 -1.7102 
Rab3a 0.342813 1.0856 1.0856 
Pick1 0.371536 1.1874 1.1874 
Nfkbib 0.374321 0.7592 -1.3172 
Nos1 0.374801 1.2927 1.2927 
Rela 0.380306 0.8689 -1.1509 
Gria1 0.386969 0.5336 -1.8742 
Egr2 0.394857 1.1844 1.1844 
Grin2c 0.397816 0.5966 -1.6761 
Igf1 0.401632 0.4222 -2.3683 
Synpo 0.402157 1.2184 1.2184 
Ntf4 0.439379 0.811 -1.233 
Prkcg 0.443998 1.0263 1.0263 
Gnai1 0.446055 0.6494 -1.5398 
Egr1 0.455676 1.0975 1.0975 
Reln 0.468039 1.0898 1.0898 
190 
 
Nfkb1 0.474956 1 1 
Egr4 0.491043 1.0349 1.0349 
Gabra5 0.505539 0.5208 -1.9201 
Prkg1 0.506751 1.1523 1.1523 
Plat 0.521329 0.928 -1.0775 
Ngfr 0.521657 0.9013 -1.1095 
Ncam1 0.530234 1.1187 1.1187 
Junb 0.540034 1.1783 1.1783 
Ppp2ca 0.541094 1.2053 1.2053 
Creb1 0.546866 0.7586 -1.3183 
Ppp1cc 0.553437 0.9584 -1.0434 
Bdnf 0.56377 0.8524 -1.1731 
Ywhaq 0.567824 1.0896 1.0896 
Rheb 0.590702 1.1023 1.1023 
Grm3 0.598756 0.7269 -1.3756 
Grin2d 0.610027 0.913 -1.0953 
Gria3 0.620373 0.8035 -1.2446 
Gria2 0.629791 0.775 -1.2904 
Ppp3ca 0.637036 1.0658 1.0658 
Ngf 0.640312 1.2567 1.2567 
Grm7 0.649373 0.9665 -1.0347 
Fos 0.657628 0.7617 -1.3129 
Grin1 0.66239 0.6966 -1.4355 
Ppp1ca 0.677821 0.9423 -1.0612 
Homer1 0.699038 1.0384 1.0384 
Ephb2 0.715093 0.8469 -1.1807 
Ppp1r14a 0.7184 1.0842 1.0842 
Camk2g 0.731992 0.8209 -1.2182 
Srf 0.75282 1.0424 1.0424 
Gria4 0.759192 0.8568 -1.1671 
Camk2a 0.760477 0.7767 -1.2874 
Mapk1 0.768616 0.8512 -1.1748 
Grip1 0.77556 0.8592 -1.1638 
Grin2a 0.777394 0.8951 -1.1172 
Prkca 0.794296 0.8962 -1.1159 
Plcg1 0.799546 1.0633 1.0633 
Egr3 0.799952 0.934 -1.0706 
Dlg4 0.806109 0.6941 -1.4407 
Grm8 0.82198 0.719 -1.3907 
Inhba 0.834537 0.7964 -1.2557 
Adcy8 0.840848 0.9416 -1.062 
191 
 
Crem 0.847683 0.8908 -1.1226 
Nptx2 0.851677 1.0505 1.0505 
Grin2b 0.856433 0.8759 -1.1417 
Ntrk2 0.858551 1.1388 1.1388 
Kif17 0.920053 0.9983 -1.0017 
Grm5 0.921761 0.7531 -1.3279 
Arc 0.93635 0.7814 -1.2798 
Grm4 0.947561 0.7526 -1.3287 
Grm2 0.968087 0.9456 -1.0576 
Adam10 0.972659 0.9301 -1.0751 
Rgs2 0.97654 1.0286 1.0286 
Grm1 0.987763 0.7249 -1.3795 
Adcy1 0.995551 0.8225 -1.2158 
 
